

## LCD for Controlled Substance Monitoring and Drugs of Abuse Testing (L35006)

### Contractor Information

**Contractor Name:** Novitas Solutions, Inc.

**Contractor Number:** 12502

**Contractor Type:** MAC B

### LCD Information

**LCD ID Number:** L35006 **Status:** A-Approved

**LCD Title:** Controlled Substance Monitoring and Drugs of Abuse Testing

**Geographic Jurisdiction:** Pennsylvania [Other Jurisdictions](#)

**Original Determination Effective Date:** 10/01/2015

**Original Determination Ending Date:**

**Revision Effective Date:** 10/01/2018

**Revision End Date:**

### CMS National Coverage Policy:

This LCD supplements but does not replace, modify or supersede existing Medicare applicable National Coverage Determinations (NCDs) or payment policy rules and regulations for drug testing. Federal statute and subsequent Medicare regulations regarding provision and payment for medical services are lengthy. They are not repeated in this LCD. Neither Medicare payment policy rules nor this LCD replace, modify or supersede applicable state statutes regarding medical practice or other health practice professions acts, definitions and/or scopes of practice. All providers who report services for Medicare payment must fully understand and follow all existing laws, regulations and rules for Medicare payment for drug testing and must properly submit only valid claims for them. Please review and understand them and apply the medical necessity provisions in the policy within the context of the manual rules. Relevant CMS manual instructions and policies may be found in the following Internet-Only Manuals (IOMs) published on the CMS Web site.

### IOM Citations:

- CMS Internet-Only Manual (IOM) Publication 100-03, *Medicare National Coverage Determinations Manual*, Chapter 1, Part 2, Section 130.6: Treatment of drug abuse.

### Change Request References:

- CMS Transmittal 653, Change Request 6852, Clinical Laboratory Fee Schedule (CLFS) - Special Instructions for Specific Test Codes (CPT Code 80100, CPT Code 80101, CPT Code 80101QW, G0430, G0430QW and G0431QW).
- CMS Transmittal 1905, Change Request 6800, February New Waived Tests.

### Social Security Act (Title XVIII) Standard References:

- Title XVIII of the Social Security Act, Section 1862(a)(1)(A) states that no Medicare payment shall be made for items or services which are not reasonable and necessary for the diagnosis or treatment of illness or injury.
- Title XVIII of the Social Security Act, Section 1862(a)(7). This section excludes routine physical examinations.
- Title XVIII of the Social Security Act, Section 1833(e) states that no payment shall be made to any provider for any claim that lacks the necessary information to process the claim.

### Federal Register References:

- 42 CFR, Section 410.32 Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions.
- 42 CFR, Section 411.15(k)(1) Particular services excluded from coverage. Any services that are not reasonable and necessary.

### Indications and Limitations of Coverage and/or Medical Necessity:

**Notice:** It is not appropriate to bill Medicare for services that are not covered (as described by this entire LCD) as if they are covered. When billing for non-covered services, use the appropriate modifier.

Compliance with the provisions in this policy may be monitored and addressed through post payment data analysis and subsequent medical review audits.

### **History/Background and/or General Information**

For purposes of clarification the term physician or clinician refers to a Physician (or other treating practitioner acting within the scope of his or her license and Medicare requirements).

Urine drug testing (UDT) provides objective information to assist clinicians in identifying the presence or absence of drugs or drug classes in the body and making treatment decisions. A presumptive drug screen is used to detect the presence of a drug in the body. A blood or urine sample may be used. However, urine is the best specimen for presumptive screening, as blood is relatively insensitive for many common drugs, including psychotropic agents, opioids, and stimulants.

Common methods of drug analysis include chromatography, immunoassay, chemical ("spot") tests, and spectrometry. Analysis is comparative, matching the properties or behavior of a substance with that of a valid reference compound (a laboratory must possess a valid reference agent for every substance that it identifies). Drugs or classes of drugs are commonly assayed by presumptive testing. A presumptive test may be followed by definitive testing, when there is a positive inconsistent finding from the presumptive test in the setting of a symptomatic patient, as described below. Typically, the "spot" chemical tests (referred to above) are urine dipsticks or multiple drug cup devices.

Examples of drugs or classes of drugs that are commonly assayed by presumptive tests, followed by definitive testing, are: alcohols, amphetamines, barbituates/sedatives, benzodiazepines, cocaine and metabolites, methadone, antihistamines, stimulants, opioid analgesics, salicylates, cardiovascular drugs, antipsychotics, cyclic antidepressants, and others. Focused drug screens, most commonly for illicit drug use, may be more useful clinically.

There should be a direct correlation between those positive findings generated from presumptive testing and those requested definitive tests to specifically confirm such findings.

This policy provides:

- The appropriate indications and expected frequency of testing for safe medication management of prescribed substances in risk stratified pain management patients or in identifying and treating substance use disorders.
- Documentation requirements, by the clinician in the patient's medical record, to support the medical necessity for drug testing on an individual patient basis.
- An overview of presumptive urine drug testing (UDT) and definitive UDT testing by various methodologies.

### **Definitions:**

By way of definition and as used in this document, the following terminology relates to the basic forms of UDT:

1. Presumptive (Qualitative) Drug Testing (hereafter called "presumptive" UDT)
  - Used when medically necessary to determine the presence or absence of drugs or drug classes in a urine sample;
  - Results expressed as negative or positive or as a numerical result;
  - Includes competitive immunoassays (IA) and thin layer chromatography.
2. Definitive (Quantitative) Confirmation (hereafter called "definitive" UDT)
  - Used when medically necessary to identify specific medications, illicit substances and metabolites; Reports the results of drugs absent or present in concentrations of ng/ml;
  - Limited to GC-MS and LC-MS/MS testing methods only.
3. Specimen Validity Testing
  - Urine specimen testing to ensure that it is consistent with normal human urine and has not been adulterated or substituted;
  - May include pH, specific gravity, oxidants and creatinine.
4. Point of Care Testing (POCT)
  - Used when medically necessary by clinicians for immediate test results for the immediate management of the patient;
  - Available when the patient and physician are in the same location;
  - IA test method that primarily identifies drug classes and a few specific drugs;
  - Platform consists of cups, dipsticks, cassettes, or strips; read by the human eye.
5. Immunoassay (IA)
  - Ordered by clinicians primarily to identify the presence or absence of drug classes and some specific drugs;
  - Biochemical tests that measure the presence above a cutoff level of a substance (drug) with the use of an antibody;
  - Read by photometric technology.
6. Standing Orders
  - Test request for a specific patient representing repetitive testing to monitor a condition or disease for a limited number of

sequential visits;

- Individualized orders for certain patients for pre-determined tests based on historical use, risk and community trend patient profiles;
- Clinician can alter the standing order.

**Note:** A “profile” differs from a “panel” in that a profile responds to the clinical risks of a particular patient, whereas a panel encourages unnecessary or excessive testing when no clinical cause exists.

#### 7. Blanket Orders

- Test request that is not for a specific patient; rather, it is an identical order for all patients in a clinician’s practice without individualized decision making at every visit.

#### 8. Reflex Testing

- Laboratory testing that is performed reflexively after initial test results to identify further diagnostic information essential to patient care.
- Testing Indications, performed as a step necessary to complete a physician’s order is not considered reflex testing.

### **Drug Test Methods**

The Clinical Laboratory Improvement Amendments (CLIA) regulates laboratory testing and requires clinical labs to be certified by their State as well as the CMS before they can accept human samples for diagnostic testing. Multiple types of CLIA certificates may be obtained based on the complexity of testing a lab conducts. CLIA levels of complexity (CLIA-waived, moderate complexity and high complexity) are addressed only as they relate to the HCPCS code description.

#### **A. Presumptive Testing Methods:**

##### 1. CLIA-waived Presumptive UDT:

- CLIA-waived presumptive UDT consist of various platforms including cards, dipsticks, cassettes and cups based on qualitative competitive immunoassay methodology with one or more analytes in the test.
  - Positive test results are presumptive or not definitive due to sensitivity and cross-reactivity limitations.
  - Negative test results do not necessarily indicate the absence of a drug or substance in the urine specimen.
  - Presumptive UDT may be ordered when it is necessary to rapidly obtain and integrate results into clinical assessment and treatment decisions.
  - This type of test should only be used when results are needed immediately.

##### 2. Presumptive UDT by FDA Approved/Cleared IA Analysis

- Chemistry analyzers with IA UDT technology are used in an office or clinical laboratory setting. When FDA approved/cleared platforms and reagents are used, testing is classified as moderately complex.
- This test may be used when less immediate test results are required.
- At no time is IA technology by chemistry analyzer analysis considered confirmatory (definitive) testing.
- Presumptive positive tests are not definitive due to sensitivity, specificity, and cross-reactivity limitations.
- Negative test results do not necessarily indicate the absence of a drug or substance in the urine specimen.

##### 3. Presumptive UDT by Laboratory Developed Test (LDT) IA Analysis:

- Similar to #2 above except only performed in a clinical laboratory setting.

#### **Limitations of Presumptive UDT:**

Presumptive UDT testing is limited for the following reasons:

- Primarily screens for drug classes rather than specific drugs, and therefore, the practitioner may not be able to determine if a different drug within the same class is causing the positive result;
- Produces erroneous results due to cross-reactivity with other compounds or does not detect all drugs within a drug class;
- Given that not all prescription medications or synthetic/analog drugs are detectable or have assays available, it is unclear as to whether other drugs are present when some tests are reported as positive;
- Cut-off may be too high to detect presence of a drug. This information could cause a practitioner to make a wrong assumption or clinical decision.

#### **B. Definitive UDT:**

Gas Chromatography coupled with Mass Spectrometry (GC-MS) and High Performance Liquid Chromatography coupled with Tandem Mass Spectrometry (LC-MS/MS) are complex technologies that use the separation capabilities of gaseous or liquid chromatography with the analytical capabilities of mass spectrometry.

Both methodologies require the competency of on-site highly trained experts in this technology and interpretation of results. While these tests require different sample preparation and analytical runs, they are quantitative tests that identify all specific drugs, metabolites, and most illicit substances and report the results as absent or present in concentrations of ng/mL.

Quantification should not be used to determine adherence with a specific dosage or time of dose of a pain medication or illicit drug for clinical purposes. Rather, the use of quantitative drug data may be important for many reasons such as in a differential patient assessment.

For example, when several opioids are present in the urine of a patient prescribed a single opioid, quantification may help the clinician decide whether the presence of the other opioids is consistent with metabolism of the prescribed opioid, opioid contamination during manufacturing, or if more than one drug within a class is being used.

Quantification may also provide information in the setting of illicit drug use. Serial creatinine-corrected quantitative values may assist in the differential assessment of ongoing drug use or cessation of drug use with continued drug excretion.

Definitive UDT is reasonable and necessary in order to:

- Identify a specific substance or metabolite that is inadequately detected by a presumptive UDT;
- Definitively identify specific drugs in a large family of drugs;
- Identify a specific substance or metabolite that is not detected by presumptive UDT such as fentanyl, meperidine, synthetic cannabinoids and other synthetic/analog drugs;
- Identify drugs when a definitive concentration of a drug is needed to guide management (e.g., discontinuation of THC use according to a treatment plan);
- Identify a negative, or confirm a positive, presumptive UDT result that is inconsistent with a patient's self-report, presentation, medical history, or current prescribed pain medication plan;
- Rule out an error as the cause of a presumptive UDT result;
- Identify non-prescribed medication or illicit use for ongoing safe prescribing of controlled substances; and
- Use in a differential assessment of medication efficacy, side effects, or drug-drug interactions.

Definitive UDT may be reasonable and necessary based on patient specific indications, including historical use, medication response, and clinical assessment, when accurate results are necessary to make clinical decisions. The clinician's rationale for the definitive UDT and the tests ordered must be documented in the patient's medical record.

### **Covered Indications for UDT**

**Group A** – Symptomatic patients, multiple drug ingestion or patients with unreliable history.

A patient who presents in a variety of medical settings with signs or symptoms of substance use toxicity will be treated presumptively to stabilize the patient while awaiting rapid, then definitive testing to determine the cause(s) of the presentation.

The need for definitive UDT is based upon rapid test findings, responses to medical interventions, and treatment plan.

A presumptive UDT should be performed as part of the evaluation and management of a patient who presents in an urgent care setting with any one of the following:

- Coma
- Altered mental status in the absence of a clinically defined toxic syndrome or toxidrome
- Severe or unexplained cardiovascular instability (cardiotoxicity)
- Unexplained metabolic or respiratory acidosis in the absence of a clinically defined toxic syndrome or toxidrome
- Seizures with an undetermined history
- To provide antagonist to specific drug

The presumptive findings, definitive drug tests ordered and reasons for the testing must be documented in the patient's medical record.

**Group B** - Diagnosis and treatment for substance abuse or dependence.

A patient in active treatment for substance use disorder (SUD) or monitoring across different phases of recovery may undergo medical management for a variety of medical conditions.

A physician who is writing prescriptions for medications to treat either the SUD or other conditions may need to know if the patient is taking substances which can interact with prescribed medications or taking prescribed medications as expected.

The risk of drug-drug interactions is inherent to the patient, and may be compounded by prescribed medications.

UDT is a medically necessary and useful component of chemical dependency diagnosis and treatment. The UDT result influences treatment and level of care decisions.

Ordered tests and testing methods (presumptive or definitive) must match the stage of screening, treatment, or recovery; the documented history; and Diagnostic and Statistical Manual of Mental Disorders (DSM V) diagnosis.

For patients with no known indicators of risk for SUDs, the clinician may screen for a broad range of commonly abused drugs

using presumptive UDT.

For patients with known indicators of risk for SUDs, the clinician may screen for a broad range of commonly abused drugs using definitive UDT.

For patients with a diagnosed SUD, the clinician should perform random UDT, at random intervals in order to properly monitor the patient. Testing profiles must be determined by the clinician based on the following medical necessity guidance criteria:

- Patient history, physical examination, and previous laboratory findings
- Stage of treatment or recovery;
- Suspected abused substance;
- Substances that may present high risk for additive or synergistic interactions with prescribed medication (e.g., benzodiazepines, alcohol).

The patient's medical record must include an appropriate testing frequency based on the stage of screening, treatment, or recovery; the rationale for the drugs/drug classes ordered; and the results must be documented in the medical record and used to direct care.

### **Group C - Treatment for patients on chronic opioid therapy (COT).**

A physician who is writing prescriptions for medications to treat chronic pain can manage a patient better if the physician knows whether the patient is consuming another medication or substance, which could suggest the possibility of SUD or lead to drug-drug interactions. Additionally, UDT may help the physician monitor for medication adherence, efficacy, side effects, and patient safety in general.

A broad cross section of the general population will develop either cancer pain syndrome or non-cancer pain which will require prolonged or chronic opioid therapy for management. The risk of addiction in this population is considered equivalent to the risk in the general population. In contrast to the population of individuals who have a history of SUD, in the cancer and non-cancer pain population the risk of SUD is inherent to the substance(s) to which the patient is exposed.

#### 1. COT UDT Testing Objectives:

- Identifies absence of prescribed medication and potential for abuse, misuse, and diversion;
- Identifies undisclosed substances, such as alcohol, unsanctioned prescription medication, or illicit substances;
- Identifies substances that contribute to adverse events or drug-drug interactions;
- Provides objectivity to the treatment plan;
- Reinforces therapeutic compliance with the patient;
- Provides additional documentation demonstrating compliance with patient evaluation and monitoring;
- Provides diagnostic information to help assess individual patient response to medications (e.g., metabolism, side effects, drug-drug interaction, etc.) over time for ongoing management of prescribed medications.

#### 2. Medical Necessity Guidance:

Criteria to establish medical necessity for drug testing must be based on patient-specific elements identified during the clinical assessment, and documented by the clinician in the patient's medical record and minimally include the following elements:

- Patient history, physical examination and previous laboratory findings;
- Current treatment plan;
- Prescribed medication(s); and
- Risk assessment plan.

National pain organizations, physician societies, and the Federation of State Medical Boards recommend a practical approach to definitive UDT for COT.

Frequency of testing beyond the baseline presumptive UDT must be based on individual patient needs substantiated by documentation in the patient's medical record. Recommendations for the ordering of presumptive and definitive UDT for patients on COT are as follows:

#### • COT Baseline Testing:

Initial presumptive or definitive COT patient testing may include amphetamine/methamphetamine, barbiturates, benzodiazepines, cocaine, methadone, oxycodone, tricyclic antidepressants, tetrahydrocannabinoid, opioids, opiates, heroin, and synthetic/analog or "designer" drugs.

#### • COT Monitoring Testing:

Ongoing testing may be medically reasonable and necessary based on the patient history, clinical assessment, including medication side effects or inefficacy, suspicious behaviors, self-escalation of dose, doctor-shopping, indications/symptoms of illegal drug use, evidence of diversion, or other clinician documented change in affect or behavioral pattern.

The frequency of testing must be based on a complete clinical assessment of the individual's risk potential for abuse and diversion using a validated risk assessment interview or questionnaire and should include the patient's response to prescribed medications and the side effects of medications.

The clinician should perform random UDT at random intervals, in order to properly monitor a patient. UDT testing does not have to be associated with an office visit.

## Drug Testing Panels

### 1. Presumptive UDT Panels

Presumptive UDT testing may be ordered as a panel because the Medicare billing codes are defined on a “per patient encounter” basis regardless of the number of analytes tested.

Presumptive UDT orders should be individualized based on clinical history and risk assessment, and must be documented in the medical record.

### 2. Definitive UDT Panels

At the current time, physician-directed definitive profile testing is reasonable and necessary when ordered for a particular patient based upon historical use and community trends. However, the same physician-defined profile is not reasonable and necessary for every patient in a physician’s practice.

Definitive UDT orders should be individualized based on clinical history and risk assessment, and must be documented in the medical record.

## Specimen Type

Urine or oral fluid is the preferred biologic specimen for testing because of the ease of collection, storage, and cost-effectiveness. UDT cannot detect the dosage of drug ingested/used, the time of use, or the means of delivery (intravenous vs. oral vs. inhaled). Detection time of a substance in urine is typically 1-3 days depending on the drug, rate of metabolism, and rate of excretion. Lipid-soluble drugs, such as marijuana, may remain in body fat and be detected upwards of a week or more.

## Other Covered Services

1. Reflex Testing by Reference Laboratories – since reference laboratories do not have access to patient-specific data, reflex testing under the following circumstances is reasonable and necessary:
  - To verify a presumptive positive UDT using definitive UDT (GC-MS or LCMS/MS) before reporting the presumptive finding to the ordering clinician and without an additional order from the clinician;

Or

  - To confirm the absence of prescribed medications when a negative result is obtained by presumptive UDT in the laboratory for a prescribed medication listed by the ordering clinician.
2. Direct to definitive UDT without a presumptive UDT is reasonable and necessary, when individualized for a particular patient, in the following circumstances:
  - To identify a specific substance or its metabolite that is in a large class of drugs, or that is inadequately detected or not detected by presumptive UDT, such as fentanyl, meperidine, synthetic cannabinoids, and other synthetic/analog drugs;
  - For use in a differential assessment of medication efficacy, side effects, or drug-drug interactions;
  - To identify non-prescribed medication or illicit substance use for ongoing safe prescribing of controlled substances, where clinician has documented concerns related to safety risks attendant to failure to identify specific substances suspected based upon clinical review and judgment; or
  - To identify drugs when a definitive concentration of a drug is needed to guide management (e.g., discontinuation of THC use according to a treatment plan).
3. Definitive testing to confirm a negative presumptive UDT result, upon the order of the clinician, is reasonable and necessary in the following circumstances:
  - The result is inconsistent with a patient’s self-report, presentation, medical history, or current prescribed medication plan (should be present in the sample);
  - Following a review of clinical findings, the clinician suspects use of a substance that is inadequately detected or not detected by a presumptive UDT; or
  - To rule out an error as the cause of a negative presumptive UDT result.
4. Definitive testing to confirm a presumptive UDT positive result, upon the order of the clinician, is reasonable and necessary when the result is inconsistent with the expected result, a patient’s self-report, presentation, medical history, or current prescribed medication plan.

## Limitations

### Non-Covered Services

1. Blanket Orders.
2. Reflex definitive UDT is not reasonable and necessary when presumptive testing is performed at point of care because the clinician may have sufficient information to manage the patient. If the clinician is not satisfied, he/she must determine the clinical appropriateness of and order specific subsequent definitive testing (e.g., the patient admits to using a particular drug, or the IA cut-off is set at such a point that is sufficiently low that the physician is satisfied with the presumptive test result).
3. Routine standing orders for all patients in a physician’s practice are not reasonable and necessary.
4. It is not reasonable and necessary for a physician to perform presumptive POCT and order presumptive IA testing from a reference

laboratory. In other words, Medicare will only pay for one presumptive test result per patient per date of service regardless of the number of billing providers.

5. It is not reasonable and necessary for a physician to perform presumptive IA testing and order presumptive IA testing from a reference laboratory with or without reflex testing. Medicare will only pay for one presumptive test result per patient per date of service regardless of the number of billing providers.
6. It is not reasonable and necessary for a reference laboratory to perform and bill IA presumptive UDT prior to definitive testing without a specific physician's order for the presumptive testing.
7. IA testing, regardless of whether it is qualitative or semi-quantitative (numerical), may not be used to "confirm" or definitively identify a presumptive test result obtained by cups, dipsticks, cards, cassettes or other IA testing methods. Definitive UDT provides specific identification or quantification by GC-MS or LCMS/MS.
8. Drug testing of two different specimen types from the same patient on the same date of service for the same drugs/metabolites/analytes.
9. UDT for medico-legal or employment purposes or to protect a physician from drug diversion charges.
10. Specimen validity testing including, but not limited to, pH, specific gravity, oxidants, creatinine.

**Notice:** This LCD imposes frequency limitations as well as diagnosis limitations that support diagnosis to procedure code automated denials. However, services performed for any given diagnosis must meet all of the indications and limitations stated in this policy, the general requirements for medical necessity as stated in CMS payment policy manuals, any and all existing CMS national coverage determinations, and all Medicare payment rules.

For frequency limitations please refer to the Utilization Guidelines section below.

As published in CMS IOM Pub. 100-08, Chapter 13, Section 13.5.1, in order to be covered under Medicare, a service shall be reasonable and necessary. When appropriate, contractors shall describe the circumstances under which the proposed LCD for the service is considered reasonable and necessary under Section 1862(a)(1)(A). Contractors shall consider a service to be reasonable and necessary if the contractor determines that the service is:

- Safe and effective.
- Not experimental or investigational (exception: routine costs of qualifying clinical trial services with dates of service on or after September 19, 2000, that meet the requirements of the Clinical Trials NCD are considered reasonable and necessary).
- Appropriate, including the duration and frequency that is considered appropriate for the service, in terms of whether it is:
  - Furnished in accordance with accepted standards of medical practice for the diagnosis or treatment of the patient's condition or to improve the function of a malformed body member.
  - Furnished in a setting appropriate to the patient's medical needs and condition.
  - Ordered and furnished by qualified personnel.
  - One that meets, but does not exceed, the patient's medical needs.
  - At least as beneficial as an existing and available medically appropriate alternative.

The redetermination process may be utilized for consideration of services performed outside of the reasonable and necessary requirements in this LCD.

### Coding Information

#### Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

12	Hospital Inpatient (Medicare Part B only)
13	Hospital Outpatient
14	Hospital - Laboratory Services Provided to Non-patients
22	Skilled Nursing - Inpatient (Medicare Part B only)
23	Skilled Nursing - Outpatient
71	Clinic - Rural Health
72	Clinic - Hospital Based or Independent Renal Dialysis Center
73	Clinic - Freestanding
77	Clinic - Federally Qualified Health Center (FQHC)
85	Critical Access Hospital

#### Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

0309	Laboratory - Other Laboratory
0300	Laboratory - General Classification
0301	Laboratory - Chemistry

**CPT/HCPCS Codes:**

**Note:** Providers are reminded to refer to the long descriptors of the CPT codes in their CPT book.

**Presumptive UDT**

- 80305 DRUG TEST(S), PRESUMPTIVE, ANY NUMBER OF DRUG CLASSES, ANY NUMBER OF DEVICES OR PROCEDURES; CAPABLE OF BEING READ BY DIRECT OPTICAL OBSERVATION ONLY (EG, UTILIZING IMMUNOASSAY [EG, DIPSTICKS, CUPS, CARDS, OR CARTRIDGES]), INCLUDES SAMPLE VALIDATION WHEN PERFORMED, PER DATE OF SERVICE
- 80306 DRUG TEST(S), PRESUMPTIVE, ANY NUMBER OF DRUG CLASSES, ANY NUMBER OF DEVICES OR PROCEDURES; READ BY INSTRUMENT ASSISTED DIRECT OPTICAL OBSERVATION (EG, UTILIZING IMMUNOASSAY [EG, DIPSTICKS, CUPS, CARDS, OR CARTRIDGES]), INCLUDES SAMPLE VALIDATION WHEN PERFORMED, PER DATE OF SERVICE
- 80307 DRUG TEST(S), PRESUMPTIVE, ANY NUMBER OF DRUG CLASSES, ANY NUMBER OF DEVICES OR PROCEDURES; BY INSTRUMENT CHEMISTRY ANALYZERS (EG, UTILIZING IMMUNOASSAY [EG, EIA, ELISA, EMIT, FPIA, IA, KIMS, RIA]), CHROMATOGRAPHY (EG, GC, HPLC), AND MASS SPECTROMETRY EITHER WITH OR WITHOUT CHROMATOGRAPHY, (EG, DART, DESI, GC-MS, GC-MS/MS, LC-MS, LC-MS/MS, LDTD, MALDI, TOF) INCLUDES SAMPLE VALIDATION WHEN PERFORMED, PER DATE OF SERVICE
- 

**Definitive UDT**

- G0480 DRUG TEST(S), DEFINITIVE, UTILIZING (1) DRUG IDENTIFICATION METHODS ABLE TO IDENTIFY INDIVIDUAL DRUGS AND DISTINGUISH BETWEEN STRUCTURAL ISOMERS (BUT NOT NECESSARILY STEREOISOMERS), INCLUDING, BUT NOT LIMITED TO GC/MS (ANY TYPE, SINGLE OR TANDEM) AND LC/MS (ANY TYPE, SINGLE OR TANDEM AND EXCLUDING IMMUNOASSAYS (E.G., IA, EIA, ELISA, EMIT, FPIA) AND ENZYMATIC METHODS (E.G., ALCOHOL DEHYDROGENASE)), (2) STABLE ISOTOPE OR OTHER UNIVERSALLY RECOGNIZED INTERNAL STANDARDS IN ALL SAMPLES (E.G., TO CONTROL FOR MATRIX EFFECTS, INTERFERENCES AND VARIATIONS IN SIGNAL STRENGTH), AND (3) METHOD OR DRUG-SPECIFIC CALIBRATION AND MATRIX-MATCHED QUALITY CONTROL MATERIAL (E.G., TO CONTROL FOR INSTRUMENT VARIATIONS AND MASS SPECTRAL DRIFT); QUALITATIVE OR QUANTITATIVE, ALL SOURCES, INCLUDES SPECIMEN VALIDITY TESTING, PER DAY; 1-7 DRUG CLASS(ES), INCLUDING METABOLITE(S) IF PERFORMED
- G0481 DRUG TEST(S), DEFINITIVE, UTILIZING (1) DRUG IDENTIFICATION METHODS ABLE TO IDENTIFY INDIVIDUAL DRUGS AND DISTINGUISH BETWEEN STRUCTURAL ISOMERS (BUT NOT NECESSARILY STEREOISOMERS), INCLUDING, BUT NOT LIMITED TO GC/MS (ANY TYPE, SINGLE OR TANDEM) AND LC/MS (ANY TYPE, SINGLE OR TANDEM AND EXCLUDING IMMUNOASSAYS (E.G., IA, EIA, ELISA, EMIT, FPIA) AND ENZYMATIC METHODS (E.G., ALCOHOL DEHYDROGENASE)), (2) STABLE ISOTOPE OR OTHER UNIVERSALLY RECOGNIZED INTERNAL STANDARDS IN ALL SAMPLES (E.G., TO CONTROL FOR MATRIX EFFECTS, INTERFERENCES AND VARIATIONS IN SIGNAL STRENGTH), AND (3) METHOD OR DRUG-SPECIFIC CALIBRATION AND MATRIX-MATCHED QUALITY CONTROL MATERIAL (E.G., TO CONTROL FOR INSTRUMENT VARIATIONS AND MASS SPECTRAL DRIFT); QUALITATIVE OR QUANTITATIVE, ALL SOURCES, INCLUDES SPECIMEN VALIDITY TESTING, PER DAY; 8-14 DRUG CLASS(ES), INCLUDING METABOLITE(S) IF PERFORMED
- G0482 DRUG TEST(S), DEFINITIVE, UTILIZING (1) DRUG IDENTIFICATION METHODS ABLE TO IDENTIFY INDIVIDUAL DRUGS AND DISTINGUISH BETWEEN STRUCTURAL ISOMERS (BUT NOT NECESSARILY STEREOISOMERS), INCLUDING, BUT NOT LIMITED TO GC/MS (ANY TYPE, SINGLE OR TANDEM) AND LC/MS (ANY TYPE, SINGLE OR TANDEM AND EXCLUDING IMMUNOASSAYS (E.G., IA, EIA, ELISA, EMIT, FPIA) AND ENZYMATIC METHODS (E.G., ALCOHOL DEHYDROGENASE)), (2) STABLE ISOTOPE OR OTHER UNIVERSALLY RECOGNIZED INTERNAL STANDARDS IN ALL SAMPLES (E.G., TO CONTROL FOR MATRIX EFFECTS, INTERFERENCES AND VARIATIONS IN SIGNAL STRENGTH), AND (3) METHOD OR DRUG-SPECIFIC CALIBRATION AND MATRIX-MATCHED QUALITY CONTROL MATERIAL (E.G., TO CONTROL FOR INSTRUMENT VARIATIONS AND MASS SPECTRAL DRIFT); QUALITATIVE OR QUANTITATIVE, ALL SOURCES, INCLUDES SPECIMEN VALIDITY TESTING, PER DAY; 15-21 DRUG CLASS(ES), INCLUDING METABOLITE(S) IF PERFORMED
- G0483 DRUG TEST(S), DEFINITIVE, UTILIZING (1) DRUG IDENTIFICATION METHODS ABLE TO IDENTIFY INDIVIDUAL DRUGS AND DISTINGUISH BETWEEN STRUCTURAL ISOMERS (BUT NOT NECESSARILY STEREOISOMERS), INCLUDING, BUT NOT LIMITED TO GC/MS (ANY TYPE, SINGLE OR TANDEM) AND LC/MS (ANY TYPE, SINGLE OR TANDEM AND EXCLUDING IMMUNOASSAYS (E.G., IA, EIA, ELISA, EMIT, FPIA) AND ENZYMATIC METHODS (E.G., ALCOHOL DEHYDROGENASE)), (2) STABLE ISOTOPE OR OTHER UNIVERSALLY RECOGNIZED INTERNAL STANDARDS IN ALL SAMPLES (E.G., TO CONTROL FOR MATRIX EFFECTS, INTERFERENCES AND VARIATIONS IN SIGNAL STRENGTH), AND (3) METHOD OR DRUG-SPECIFIC CALIBRATION AND MATRIX-MATCHED QUALITY CONTROL MATERIAL (E.G., TO CONTROL FOR INSTRUMENT VARIATIONS AND MASS SPECTRAL DRIFT); QUALITATIVE OR QUANTITATIVE, ALL SOURCES, INCLUDES SPECIMEN VALIDITY TESTING, PER DAY; 22 OR MORE DRUG CLASS(ES), INCLUDING METABOLITE(S) IF PERFORMED

DRUG TEST(S), DEFINITIVE, UTILIZING DRUG IDENTIFICATION METHODS ABLE TO IDENTIFY INDIVIDUAL DRUGS AND DISTINGUISH BETWEEN STRUCTURAL ISOMERS (BUT NOT NECESSARILY STEREOISOMERS), INCLUDING BUT NOT LIMITED TO GC/MS (ANY TYPE, SINGLE OR TANDEM) AND LC/MS (ANY TYPE, SINGLE OR TANDEM), EXCLUDING IMMUNOASSAYS (E.G., IA, EIA, ELISA, EMIT, FPIA) AND ENZYMATIC METHODS (E.G., ALCOHOL DEHYDROGENASE), PERFORMED WITHOUT METHOD OR DRUG-SPECIFIC CALIBRATION, WITHOUT MATRIX-MATCHED QUALITY CONTROL MATERIAL, OR WITHOUT USE OF STABLE ISOTOPE OR OTHER UNIVERSALLY RECOGNIZED INTERNAL STANDARD(S) FOR EACH DRUG, DRUG METABOLITE OR DRUG CLASS PER SPECIMEN; QUALITATIVE OR QUANTITATIVE, ALL SOURCES, INCLUDES SPECIMEN VALIDITY TESTING, PER DAY, ANY NUMBER OF DRUG CLASSES

## ICD-10 Codes that Support Medical Necessity:

It is the provider's responsibility to select codes carried out to the highest level of specificity and selected from the ICD-10-CM code book appropriate to the year in which the service is rendered for the claim(s) submitted.

Physicians are to select the most appropriate diagnosis code. Labs are not to prepopulate requisition forms with diagnosis codes.

### Presumptive UDT

E87.2	Acidosis
F10.120 *	Alcohol abuse with intoxication, uncomplicated
F11.20 *	Opioid dependence, uncomplicated
F12.120 *	Cannabis abuse with intoxication, uncomplicated
F12.220 *	Cannabis dependence with intoxication, uncomplicated
F13.120 *	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated
F14.120 *	Cocaine abuse with intoxication, uncomplicated
F14.220 *	Cocaine dependence with intoxication, uncomplicated
F16.120 *	Hallucinogen abuse with intoxication, uncomplicated
F18.10 *	Inhalant abuse, uncomplicated
F18.120 *	Inhalant abuse with intoxication, uncomplicated
F18.90 *	Inhalant use, unspecified, uncomplicated
F19.20 *	Other psychoactive substance dependence, uncomplicated
F20.0	Paranoid schizophrenia
F20.1	Disorganized schizophrenia
F20.2	Catatonic schizophrenia
F20.89	Other schizophrenia
F55.3 *	Abuse of steroids or hormones
F55.4 *	Abuse of vitamins
F55.8 *	Abuse of other non-psychoactive substances
G40.301	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticus
G40.309	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status epilepticus
G40.311	Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticus
G40.319	Generalized idiopathic epilepsy and epileptic syndromes, intractable, without status epilepticus
G40.901	Epilepsy, unspecified, not intractable, with status epilepticus
G40.909	Epilepsy, unspecified, not intractable, without status epilepticus
G40.911	Epilepsy, unspecified, intractable, with status epilepticus
G40.919	Epilepsy, unspecified, intractable, without status epilepticus
I44.0	Atrioventricular block, first degree
I44.1	Atrioventricular block, second degree
I44.30	Unspecified atrioventricular block
I45.81	Long QT syndrome
I47.1	Supraventricular tachycardia
I47.2	Ventricular tachycardia

M25.50	Pain in unspecified joint
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region
M51.14	Intervertebral disc disorders with radiculopathy, thoracic region
M51.15	Intervertebral disc disorders with radiculopathy, thoracolumbar region
M51.16	Intervertebral disc disorders with radiculopathy, lumbar region
M51.17	Intervertebral disc disorders with radiculopathy, lumbosacral region
M51.36	Other intervertebral disc degeneration, lumbar region
M51.37	Other intervertebral disc degeneration, lumbosacral region
M54.10	Radiculopathy, site unspecified
M54.14	Radiculopathy, thoracic region
M54.15	Radiculopathy, thoracolumbar region
M54.16	Radiculopathy, lumbar region
M54.17	Radiculopathy, lumbosacral region
M54.18	Radiculopathy, sacral and sacrococcygeal region
M54.2	Cervicalgia
M54.5	Low back pain
M60.811	Other myositis, right shoulder
M60.812	Other myositis, left shoulder
M60.821	Other myositis, right upper arm
M60.822	Other myositis, left upper arm
M60.831	Other myositis, right forearm
M60.832	Other myositis, left forearm
M60.841	Other myositis, right hand
M60.842	Other myositis, left hand
M60.851	Other myositis, right thigh
M60.852	Other myositis, left thigh
M60.861	Other myositis, right lower leg
M60.862	Other myositis, left lower leg
M60.871	Other myositis, right ankle and foot
M60.872	Other myositis, left ankle and foot
M60.88	Other myositis, other site
M60.89	Other myositis, multiple sites
M79.11	Myalgia of mastication muscle
M79.12	Myalgia of auxiliary muscles, head and neck
M79.18	Myalgia, other site
M79.2	Neuralgia and neuritis, unspecified
M79.7	Fibromyalgia
R40.0	Somnolence
R40.1	Stupor
R40.2111	Coma scale, eyes open, never, in the field [EMT or ambulance]
R40.2112	Coma scale, eyes open, never, at arrival to emergency department
R40.2113	Coma scale, eyes open, never, at hospital admission
R40.2114	Coma scale, eyes open, never, 24 hours or more after hospital admission
R40.2121	Coma scale, eyes open, to pain, in the field [EMT or ambulance]
R40.2122	Coma scale, eyes open, to pain, at arrival to emergency department
R40.2123	Coma scale, eyes open, to pain, at hospital admission

R40.2124	Coma scale, eyes open, to pain, 24 hours or more after hospital admission
R40.2211	Coma scale, best verbal response, none, in the field [EMT or ambulance]
R40.2212	Coma scale, best verbal response, none, at arrival to emergency department
R40.2213	Coma scale, best verbal response, none, at hospital admission
R40.2214	Coma scale, best verbal response, none, 24 hours or more after hospital admission
R40.2221	Coma scale, best verbal response, incomprehensible words, in the field [EMT or ambulance]
R40.2222	Coma scale, best verbal response, incomprehensible words, at arrival to emergency department
R40.2223	Coma scale, best verbal response, incomprehensible words, at hospital admission
R40.2224	Coma scale, best verbal response, incomprehensible words, 24 hours or more after hospital admission
R40.2311	Coma scale, best motor response, none, in the field [EMT or ambulance]
R40.2312	Coma scale, best motor response, none, at arrival to emergency department
R40.2313	Coma scale, best motor response, none, at hospital admission
R40.2314	Coma scale, best motor response, none, 24 hours or more after hospital admission
R40.2321	Coma scale, best motor response, extension, in the field [EMT or ambulance]
R40.2322	Coma scale, best motor response, extension, at arrival to emergency department
R40.2323	Coma scale, best motor response, extension, at hospital admission
R40.2324	Coma scale, best motor response, extension, 24 hours or more after hospital admission
R40.2341	Coma scale, best motor response, flexion withdrawal, in the field [EMT or ambulance]
R40.2342	Coma scale, best motor response, flexion withdrawal, at arrival to emergency department
R40.2343	Coma scale, best motor response, flexion withdrawal, at hospital admission
R40.2344	Coma scale, best motor response, flexion withdrawal, 24 hours or more after hospital admission
R40.2410	Glasgow coma scale score 13-15, unspecified time
R40.2411	Glasgow coma scale score 13-15, in the field [EMT or ambulance]
R40.2412	Glasgow coma scale score 13-15, at arrival to emergency department
R40.2413	Glasgow coma scale score 13-15, at hospital admission
R40.2414	Glasgow coma scale score 13-15, 24 hours or more after hospital admission
R40.2420	Glasgow coma scale score 9-12, unspecified time
R40.2421	Glasgow coma scale score 9-12, in the field [EMT or ambulance]
R40.2422	Glasgow coma scale score 9-12, at arrival to emergency department
R40.2423	Glasgow coma scale score 9-12, at hospital admission
R40.2424	Glasgow coma scale score 9-12, 24 hours or more after hospital admission
R40.2430	Glasgow coma scale score 3-8, unspecified time
R40.2431	Glasgow coma scale score 3-8, in the field [EMT or ambulance]
R40.2432	Glasgow coma scale score 3-8, at arrival to emergency department
R40.2433	Glasgow coma scale score 3-8, at hospital admission
R40.2434	Glasgow coma scale score 3-8, 24 hours or more after hospital admission
R40.2440	Other coma, without documented Glasgow coma scale score, or with partial score reported, unspecified time
R40.2441	Other coma, without documented Glasgow coma scale score, or with partial score reported, in the field [EMT or ambulance]
R40.2442	Other coma, without documented Glasgow coma scale score, or with partial score reported, at arrival to emergency department
R40.2443	Other coma, without documented Glasgow coma scale score, or with partial score reported, at hospital admission
R40.2444	Other coma, without documented Glasgow coma scale score, or with partial score reported, 24 hours or more after hospital admission
R41.0	Disorientation, unspecified
R41.82	Altered mental status, unspecified
R44.0	Auditory hallucinations
R44.3	Hallucinations, unspecified
R56.9	Unspecified convulsions
T39.011A	Poisoning by aspirin, accidental (unintentional), initial encounter
T39.012A	Poisoning by aspirin, intentional self-harm, initial encounter
T39.013A	Poisoning by aspirin, assault, initial encounter

T39.014A	Poisoning by aspirin, undetermined, initial encounter
T39.091A	Poisoning by salicylates, accidental (unintentional), initial encounter
T39.092A	Poisoning by salicylates, intentional self-harm, initial encounter
T39.093A	Poisoning by salicylates, assault, initial encounter
T39.094A	Poisoning by salicylates, undetermined, initial encounter
T39.1X1A	Poisoning by 4-Aminophenol derivatives, accidental (unintentional), initial encounter
T39.1X2A	Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter
T39.1X3A	Poisoning by 4-Aminophenol derivatives, assault, initial encounter
T39.1X4A	Poisoning by 4-Aminophenol derivatives, undetermined, initial encounter
T39.2X1A	Poisoning by pyrazolone derivatives, accidental (unintentional), initial encounter
T39.2X2A	Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter
T39.2X3A	Poisoning by pyrazolone derivatives, assault, initial encounter
T39.2X4A	Poisoning by pyrazolone derivatives, undetermined, initial encounter
T39.311A	Poisoning by propionic acid derivatives, accidental (unintentional), initial encounter
T39.312A	Poisoning by propionic acid derivatives, intentional self-harm, initial encounter
T39.313A	Poisoning by propionic acid derivatives, assault, initial encounter
T39.314A	Poisoning by propionic acid derivatives, undetermined, initial encounter
T39.391A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], accidental (unintentional), initial encounter
T39.392A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter
T39.393A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, initial encounter
T39.394A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], undetermined, initial encounter
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter
T40.0X3A	Poisoning by opium, assault, initial encounter
T40.0X4A	Poisoning by opium, undetermined, initial encounter
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter
T40.1X3A	Poisoning by heroin, assault, initial encounter
T40.1X4A	Poisoning by heroin, undetermined, initial encounter
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter
T40.2X3A	Poisoning by other opioids, assault, initial encounter
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter
T40.3X3A	Poisoning by methadone, assault, initial encounter
T40.3X4A	Poisoning by methadone, undetermined, initial encounter
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter
T40.5X1A	Poisoning by cocaine, accidental (unintentional), initial encounter
T40.5X2A	Poisoning by cocaine, intentional self-harm, initial encounter
T40.5X3A	Poisoning by cocaine, assault, initial encounter
T40.5X4A	Poisoning by cocaine, undetermined, initial encounter
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter

T40.693A	Poisoning by other narcotics, assault, initial encounter
T40.694A	Poisoning by other narcotics, undetermined, initial encounter
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter
T40.7X2A	Poisoning by cannabis (derivatives), intentional self-harm, initial encounter
T40.7X3A	Poisoning by cannabis (derivatives), assault, initial encounter
T40.7X4A	Poisoning by cannabis (derivatives), undetermined, initial encounter
T40.8X2A	Poisoning by lysergide [LSD], intentional self-harm, initial encounter
T40.8X3A	Poisoning by lysergide [LSD], assault, initial encounter
T40.8X4A	Poisoning by lysergide [LSD], undetermined, initial encounter
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter
T40.902A	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter
T40.903A	Poisoning by unspecified psychodysleptics [hallucinogens], assault, initial encounter
T40.904A	Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, initial encounter
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter
T40.992A	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter
T40.993A	Poisoning by other psychodysleptics [hallucinogens], assault, initial encounter
T40.994A	Poisoning by other psychodysleptics [hallucinogens], undetermined, initial encounter
T42.0X1A	Poisoning by hydantoin derivatives, accidental (unintentional), initial encounter
T42.0X2A	Poisoning by hydantoin derivatives, intentional self-harm, initial encounter
T42.0X3A	Poisoning by hydantoin derivatives, assault, initial encounter
T42.0X4A	Poisoning by hydantoin derivatives, undetermined, initial encounter
T42.3X1A	Poisoning by barbiturates, accidental (unintentional), initial encounter
T42.3X2A	Poisoning by barbiturates, intentional self-harm, initial encounter
T42.3X3A	Poisoning by barbiturates, assault, initial encounter
T42.3X4A	Poisoning by barbiturates, undetermined, initial encounter
T42.4X1A	Poisoning by benzodiazepines, accidental (unintentional), initial encounter
T42.4X2A	Poisoning by benzodiazepines, intentional self-harm, initial encounter
T42.4X3A	Poisoning by benzodiazepines, assault, initial encounter
T42.4X4A	Poisoning by benzodiazepines, undetermined, initial encounter
T42.6X1A	Poisoning by other antiepileptic and sedative-hypnotic drugs, accidental (unintentional), initial encounter
T42.6X2A	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter
T42.6X3A	Poisoning by other antiepileptic and sedative-hypnotic drugs, assault, initial encounter
T42.6X4A	Poisoning by other antiepileptic and sedative-hypnotic drugs, undetermined, initial encounter
T43.011A	Poisoning by tricyclic antidepressants, accidental (unintentional), initial encounter
T43.012A	Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter
T43.013A	Poisoning by tricyclic antidepressants, assault, initial encounter
T43.014A	Poisoning by tricyclic antidepressants, undetermined, initial encounter
T43.021A	Poisoning by tetracyclic antidepressants, accidental (unintentional), initial encounter
T43.022A	Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter
T43.023A	Poisoning by tetracyclic antidepressants, assault, initial encounter
T43.024A	Poisoning by tetracyclic antidepressants, undetermined, initial encounter
T43.1X1A	Poisoning by monoamine-oxidase-inhibitor antidepressants, accidental (unintentional), initial encounter
T43.1X2A	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter
T43.1X3A	Poisoning by monoamine-oxidase-inhibitor antidepressants, assault, initial encounter
T43.1X4A	Poisoning by monoamine-oxidase-inhibitor antidepressants, undetermined, initial encounter
T43.201A	Poisoning by unspecified antidepressants, accidental (unintentional), initial encounter
T43.202A	Poisoning by unspecified antidepressants, intentional self-harm, initial encounter
T43.203A	Poisoning by unspecified antidepressants, assault, initial encounter
T43.204A	Poisoning by unspecified antidepressants, undetermined, initial encounter
T43.211A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, accidental (unintentional), initial encounter

T43.212A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter
T43.213A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, assault, initial encounter
T43.214A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, undetermined, initial encounter
T43.221A	Poisoning by selective serotonin reuptake inhibitors, accidental (unintentional), initial encounter
T43.222A	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter
T43.223A	Poisoning by selective serotonin reuptake inhibitors, assault, initial encounter
T43.224A	Poisoning by selective serotonin reuptake inhibitors, undetermined, initial encounter
T43.291A	Poisoning by other antidepressants, accidental (unintentional), initial encounter
T43.292A	Poisoning by other antidepressants, intentional self-harm, initial encounter
T43.293A	Poisoning by other antidepressants, assault, initial encounter
T43.294A	Poisoning by other antidepressants, undetermined, initial encounter
T43.3X1A	Poisoning by phenothiazine antipsychotics and neuroleptics, accidental (unintentional), initial encounter
T43.3X2A	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter
T43.3X3A	Poisoning by phenothiazine antipsychotics and neuroleptics, assault, initial encounter
T43.3X4A	Poisoning by phenothiazine antipsychotics and neuroleptics, undetermined, initial encounter
T43.4X1A	Poisoning by butyrophenone and thiothixene neuroleptics, accidental (unintentional), initial encounter
T43.4X2A	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter
T43.4X3A	Poisoning by butyrophenone and thiothixene neuroleptics, assault, initial encounter
T43.4X4A	Poisoning by butyrophenone and thiothixene neuroleptics, undetermined, initial encounter
T43.501A	Poisoning by unspecified antipsychotics and neuroleptics, accidental (unintentional), initial encounter
T43.502A	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter
T43.503A	Poisoning by unspecified antipsychotics and neuroleptics, assault, initial encounter
T43.504A	Poisoning by unspecified antipsychotics and neuroleptics, undetermined, initial encounter
T43.591A	Poisoning by other antipsychotics and neuroleptics, accidental (unintentional), initial encounter
T43.592A	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter
T43.593A	Poisoning by other antipsychotics and neuroleptics, assault, initial encounter
T43.594A	Poisoning by other antipsychotics and neuroleptics, undetermined, initial encounter
T43.601A	Poisoning by unspecified psychostimulants, accidental (unintentional), initial encounter
T43.602A	Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter
T43.603A	Poisoning by unspecified psychostimulants, assault, initial encounter
T43.604A	Poisoning by unspecified psychostimulants, undetermined, initial encounter
T43.611A	Poisoning by caffeine, accidental (unintentional), initial encounter
T43.612A	Poisoning by caffeine, intentional self-harm, initial encounter
T43.613A	Poisoning by caffeine, assault, initial encounter
T43.614A	Poisoning by caffeine, undetermined, initial encounter
T43.621A	Poisoning by amphetamines, accidental (unintentional), initial encounter
T43.622A	Poisoning by amphetamines, intentional self-harm, initial encounter
T43.623A	Poisoning by amphetamines, assault, initial encounter
T43.624A	Poisoning by amphetamines, undetermined, initial encounter
T43.631A	Poisoning by methylphenidate, accidental (unintentional), initial encounter
T43.632A	Poisoning by methylphenidate, intentional self-harm, initial encounter
T43.633A	Poisoning by methylphenidate, assault, initial encounter
T43.634A	Poisoning by methylphenidate, undetermined, initial encounter
T43.641A	Poisoning by ecstasy, accidental (unintentional), initial encounter
T43.642A	Poisoning by ecstasy, intentional self-harm, initial encounter
T43.643A	Poisoning by ecstasy, assault, initial encounter
T43.644A	Poisoning by ecstasy, undetermined, initial encounter
T43.691A	Poisoning by other psychostimulants, accidental (unintentional), initial encounter
T43.692A	Poisoning by other psychostimulants, intentional self-harm, initial encounter
T43.693A	Poisoning by other psychostimulants, assault, initial encounter
T43.694A	Poisoning by other psychostimulants, undetermined, initial encounter

T43.8X1A	Poisoning by other psychotropic drugs, accidental (unintentional), initial encounter
T43.8X2A	Poisoning by other psychotropic drugs, intentional self-harm, initial encounter
T43.8X3A	Poisoning by other psychotropic drugs, assault, initial encounter
T43.8X4A	Poisoning by other psychotropic drugs, undetermined, initial encounter
T43.91XA	Poisoning by unspecified psychotropic drug, accidental (unintentional), initial encounter
T43.92XA	Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter
T43.93XA	Poisoning by unspecified psychotropic drug, assault, initial encounter
T43.94XA	Poisoning by unspecified psychotropic drug, undetermined, initial encounter
T45.0X1A	Poisoning by antiallergic and antiemetic drugs, accidental (unintentional), initial encounter
T45.0X2A	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter
T45.0X3A	Poisoning by antiallergic and antiemetic drugs, assault, initial encounter
T45.0X4A	Poisoning by antiallergic and antiemetic drugs, undetermined, initial encounter
T46.0X1A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, accidental (unintentional), initial encounter
T46.0X2A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter
T46.0X3A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, assault, initial encounter
T46.0X4A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, undetermined, initial encounter
T50.901A	Poisoning by unspecified drugs, medicaments and biological substances, accidental (unintentional), initial encounter
T50.902A	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter
T50.903A	Poisoning by unspecified drugs, medicaments and biological substances, assault, initial encounter
T50.904A	Poisoning by unspecified drugs, medicaments and biological substances, undetermined, initial encounter
T50.991A	Poisoning by other drugs, medicaments and biological substances, accidental (unintentional), initial encounter
Z71.51 *	Drug abuse counseling and surveillance of drug abuser
Z79.891	Long term (current) use of opiate analgesic
Z79.899	Other long term (current) drug therapy
Z91.120	Patient's intentional underdosing of medication regimen due to financial hardship
Z91.128	Patient's intentional underdosing of medication regimen for other reason
Z91.130	Patient's unintentional underdosing of medication regimen due to age-related debility
Z91.138	Patient's unintentional underdosing of medication regimen for other reason
Z91.14	Patient's other noncompliance with medication regimen
Z91.19	Patient's noncompliance with other medical treatment and regimen

\*F10.120, F11.20, F12.120, F12.220, F13.120, F14.120, F14.220, F16.120, F18.10, F18.120, F18.90, F19.20, F55.3, F55.4, F55.8: Signify diagnosis codes which are exempt from Group 1 codes one per calendar year frequency limit, given their status as substance use disorder (SUD) codes.

\*Report monitoring of patient compliance in a drug treatment program using Z71.51 as the primary diagnosis and the specific drug dependence diagnosis as the secondary diagnosis.

Physicians are to select the most appropriate diagnosis code. Labs are not to prepopulate requisition forms with diagnosis codes.

#### Definitive UDT

E03.5	Myxedema coma
E87.2	Acidosis
F10.11	Alcohol abuse, in remission
F10.120	Alcohol abuse with intoxication, uncomplicated
F10.121	Alcohol abuse with intoxication delirium
F10.129	Alcohol abuse with intoxication, unspecified
F10.14	Alcohol abuse with alcohol-induced mood disorder
F10.150	Alcohol abuse with alcohol-induced psychotic disorder with delusions
F10.151	Alcohol abuse with alcohol-induced psychotic disorder with hallucinations
F10.159	Alcohol abuse with alcohol-induced psychotic disorder, unspecified

F10.180	Alcohol abuse with alcohol-induced anxiety disorder
F10.181	Alcohol abuse with alcohol-induced sexual dysfunction
F10.182	Alcohol abuse with alcohol-induced sleep disorder
F10.188	Alcohol abuse with other alcohol-induced disorder
F10.19	Alcohol abuse with unspecified alcohol-induced disorder
F10.20	Alcohol dependence, uncomplicated
F10.21	Alcohol dependence, in remission
F10.220	Alcohol dependence with intoxication, uncomplicated
F10.221	Alcohol dependence with intoxication delirium
F10.229	Alcohol dependence with intoxication, unspecified
F10.230	Alcohol dependence with withdrawal, uncomplicated
F10.231	Alcohol dependence with withdrawal delirium
F10.232	Alcohol dependence with withdrawal with perceptual disturbance
F10.239	Alcohol dependence with withdrawal, unspecified
F10.24	Alcohol dependence with alcohol-induced mood disorder
F10.250	Alcohol dependence with alcohol-induced psychotic disorder with delusions
F10.251	Alcohol dependence with alcohol-induced psychotic disorder with hallucinations
F10.259	Alcohol dependence with alcohol-induced psychotic disorder, unspecified
F10.26	Alcohol dependence with alcohol-induced persisting amnesic disorder
F10.27	Alcohol dependence with alcohol-induced persisting dementia
F10.280	Alcohol dependence with alcohol-induced anxiety disorder
F10.281	Alcohol dependence with alcohol-induced sexual dysfunction
F10.282	Alcohol dependence with alcohol-induced sleep disorder
F10.288	Alcohol dependence with other alcohol-induced disorder
F10.29	Alcohol dependence with unspecified alcohol-induced disorder
F10.920	Alcohol use, unspecified with intoxication, uncomplicated
F10.921	Alcohol use, unspecified with intoxication delirium
F10.929	Alcohol use, unspecified with intoxication, unspecified
F10.94	Alcohol use, unspecified with alcohol-induced mood disorder
F10.950	Alcohol use, unspecified with alcohol-induced psychotic disorder with delusions
F10.951	Alcohol use, unspecified with alcohol-induced psychotic disorder with hallucinations
F10.959	Alcohol use, unspecified with alcohol-induced psychotic disorder, unspecified
F10.96	Alcohol use, unspecified with alcohol-induced persisting amnesic disorder
F10.97	Alcohol use, unspecified with alcohol-induced persisting dementia
F10.980	Alcohol use, unspecified with alcohol-induced anxiety disorder
F10.981	Alcohol use, unspecified with alcohol-induced sexual dysfunction
F10.982	Alcohol use, unspecified with alcohol-induced sleep disorder
F10.988	Alcohol use, unspecified with other alcohol-induced disorder
F10.99	Alcohol use, unspecified with unspecified alcohol-induced disorder
F11.11	Opioid abuse, in remission
F11.120	Opioid abuse with intoxication, uncomplicated
F11.121	Opioid abuse with intoxication delirium
F11.122	Opioid abuse with intoxication with perceptual disturbance
F11.129	Opioid abuse with intoxication, unspecified
F11.14	Opioid abuse with opioid-induced mood disorder
F11.150	Opioid abuse with opioid-induced psychotic disorder with delusions
F11.151	Opioid abuse with opioid-induced psychotic disorder with hallucinations
F11.159	Opioid abuse with opioid-induced psychotic disorder, unspecified
F11.181	Opioid abuse with opioid-induced sexual dysfunction
F11.182	Opioid abuse with opioid-induced sleep disorder
F11.188	Opioid abuse with other opioid-induced disorder

F11.19	Opioid abuse with unspecified opioid-induced disorder
F11.20	Opioid dependence, uncomplicated
F11.21	Opioid dependence, in remission
F11.220	Opioid dependence with intoxication, uncomplicated
F11.221	Opioid dependence with intoxication delirium
F11.222	Opioid dependence with intoxication with perceptual disturbance
F11.229	Opioid dependence with intoxication, unspecified
F11.23	Opioid dependence with withdrawal
F11.24	Opioid dependence with opioid-induced mood disorder
F11.250	Opioid dependence with opioid-induced psychotic disorder with delusions
F11.251	Opioid dependence with opioid-induced psychotic disorder with hallucinations
F11.281	Opioid dependence with opioid-induced sexual dysfunction
F11.282	Opioid dependence with opioid-induced sleep disorder
F11.288	Opioid dependence with other opioid-induced disorder
F11.29	Opioid dependence with unspecified opioid-induced disorder
F11.90	Opioid use, unspecified, uncomplicated
F11.920	Opioid use, unspecified with intoxication, uncomplicated
F11.921	Opioid use, unspecified with intoxication delirium
F11.922	Opioid use, unspecified with intoxication with perceptual disturbance
F11.929	Opioid use, unspecified with intoxication, unspecified
F11.93	Opioid use, unspecified with withdrawal
F11.94	Opioid use, unspecified with opioid-induced mood disorder
F11.950	Opioid use, unspecified with opioid-induced psychotic disorder with delusions
F11.951	Opioid use, unspecified with opioid-induced psychotic disorder with hallucinations
F11.959	Opioid use, unspecified with opioid-induced psychotic disorder, unspecified
F11.981	Opioid use, unspecified with opioid-induced sexual dysfunction
F11.982	Opioid use, unspecified with opioid-induced sleep disorder
F11.988	Opioid use, unspecified with other opioid-induced disorder
F11.99	Opioid use, unspecified with unspecified opioid-induced disorder
F12.11	Cannabis abuse, in remission
F12.120	Cannabis abuse with intoxication, uncomplicated
F12.121	Cannabis abuse with intoxication delirium
F12.122	Cannabis abuse with intoxication with perceptual disturbance
F12.129	Cannabis abuse with intoxication, unspecified
F12.150	Cannabis abuse with psychotic disorder with delusions
F12.151	Cannabis abuse with psychotic disorder with hallucinations
F12.159	Cannabis abuse with psychotic disorder, unspecified
F12.180	Cannabis abuse with cannabis-induced anxiety disorder
F12.188	Cannabis abuse with other cannabis-induced disorder
F12.19	Cannabis abuse with unspecified cannabis-induced disorder
F12.20	Cannabis dependence, uncomplicated
F12.21	Cannabis dependence, in remission
F12.220	Cannabis dependence with intoxication, uncomplicated
F12.221	Cannabis dependence with intoxication delirium
F12.222	Cannabis dependence with intoxication with perceptual disturbance
F12.229	Cannabis dependence with intoxication, unspecified
F12.23	Cannabis dependence with withdrawal
F12.250	Cannabis dependence with psychotic disorder with delusions
F12.251	Cannabis dependence with psychotic disorder with hallucinations
F12.259	Cannabis dependence with psychotic disorder, unspecified
F12.280	Cannabis dependence with cannabis-induced anxiety disorder

F12.288	Cannabis dependence with other cannabis-induced disorder
F12.29	Cannabis dependence with unspecified cannabis-induced disorder
F12.90	Cannabis use, unspecified, uncomplicated
F12.920	Cannabis use, unspecified with intoxication, uncomplicated
F12.921	Cannabis use, unspecified with intoxication delirium
F12.922	Cannabis use, unspecified with intoxication with perceptual disturbance
F12.929	Cannabis use, unspecified with intoxication, unspecified
F12.93	Cannabis use, unspecified with withdrawal
F12.950	Cannabis use, unspecified with psychotic disorder with delusions
F12.951	Cannabis use, unspecified with psychotic disorder with hallucinations
F12.959	Cannabis use, unspecified with psychotic disorder, unspecified
F12.980	Cannabis use, unspecified with anxiety disorder
F12.988	Cannabis use, unspecified with other cannabis-induced disorder
F12.99	Cannabis use, unspecified with unspecified cannabis-induced disorder
F13.10	Sedative, hypnotic or anxiolytic abuse, uncomplicated
F13.11	Sedative, hypnotic or anxiolytic abuse, in remission
F13.120	Sedative, hypnotic or anxiolytic abuse with intoxication, uncomplicated
F13.121	Sedative, hypnotic or anxiolytic abuse with intoxication delirium
F13.129	Sedative, hypnotic or anxiolytic abuse with intoxication, unspecified
F13.14	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced mood disorder
F13.150	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions
F13.151	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations
F13.159	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified
F13.180	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced anxiety disorder
F13.181	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sexual dysfunction
F13.182	Sedative, hypnotic or anxiolytic abuse with sedative, hypnotic or anxiolytic-induced sleep disorder
F13.188	Sedative, hypnotic or anxiolytic abuse with other sedative, hypnotic or anxiolytic-induced disorder
F13.19	Sedative, hypnotic or anxiolytic abuse with unspecified sedative, hypnotic or anxiolytic-induced disorder
F13.20	Sedative, hypnotic or anxiolytic dependence, uncomplicated
F13.21	Sedative, hypnotic or anxiolytic dependence, in remission
F13.220	Sedative, hypnotic or anxiolytic dependence with intoxication, uncomplicated
F13.221	Sedative, hypnotic or anxiolytic dependence with intoxication delirium
F13.229	Sedative, hypnotic or anxiolytic dependence with intoxication, unspecified
F13.230	Sedative, hypnotic or anxiolytic dependence with withdrawal, uncomplicated
F13.231	Sedative, hypnotic or anxiolytic dependence with withdrawal delirium
F13.232	Sedative, hypnotic or anxiolytic dependence with withdrawal with perceptual disturbance
F13.239	Sedative, hypnotic or anxiolytic dependence with withdrawal, unspecified
F13.24	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced mood disorder
F13.250	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions
F13.251	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations
F13.259	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified
F13.26	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder
F13.27	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced persisting dementia
F13.280	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced anxiety disorder
F13.281	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sexual dysfunction
F13.282	Sedative, hypnotic or anxiolytic dependence with sedative, hypnotic or anxiolytic-induced sleep disorder
F13.288	Sedative, hypnotic or anxiolytic dependence with other sedative, hypnotic or anxiolytic-induced disorder

F13.29	Sedative, hypnotic or anxiolytic dependence with unspecified sedative, hypnotic or anxiolytic-induced disorder
F13.90	Sedative, hypnotic, or anxiolytic use, unspecified, uncomplicated
F13.920	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, uncomplicated
F13.921	Sedative, hypnotic or anxiolytic use, unspecified with intoxication delirium
F13.929	Sedative, hypnotic or anxiolytic use, unspecified with intoxication, unspecified
F13.930	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, uncomplicated
F13.931	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal delirium
F13.932	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal with perceptual disturbances
F13.939	Sedative, hypnotic or anxiolytic use, unspecified with withdrawal, unspecified
F13.94	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced mood disorder
F13.950	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with delusions
F13.951	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder with hallucinations
F13.959	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced psychotic disorder, unspecified
F13.96	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting amnesic disorder
F13.97	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia
F13.980	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced anxiety disorder
F13.981	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sexual dysfunction
F13.982	Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced sleep disorder
F13.988	Sedative, hypnotic or anxiolytic use, unspecified with other sedative, hypnotic or anxiolytic-induced disorder
F13.99	Sedative, hypnotic or anxiolytic use, unspecified with unspecified sedative, hypnotic or anxiolytic-induced disorder
F14.10	Cocaine abuse, uncomplicated
F14.11	Cocaine abuse, in remission
F14.120	Cocaine abuse with intoxication, uncomplicated
F14.121	Cocaine abuse with intoxication with delirium
F14.122	Cocaine abuse with intoxication with perceptual disturbance
F14.14	Cocaine abuse with cocaine-induced mood disorder
F14.150	Cocaine abuse with cocaine-induced psychotic disorder with delusions
F14.151	Cocaine abuse with cocaine-induced psychotic disorder with hallucinations
F14.159	Cocaine abuse with cocaine-induced psychotic disorder, unspecified
F14.180	Cocaine abuse with cocaine-induced anxiety disorder
F14.181	Cocaine abuse with cocaine-induced sexual dysfunction
F14.182	Cocaine abuse with cocaine-induced sleep disorder
F14.188	Cocaine abuse with other cocaine-induced disorder
F14.19	Cocaine abuse with unspecified cocaine-induced disorder
F14.20	Cocaine dependence, uncomplicated
F14.220	Cocaine dependence with intoxication, uncomplicated
F14.221	Cocaine dependence with intoxication delirium
F14.222	Cocaine dependence with intoxication with perceptual disturbance
F14.229	Cocaine dependence with intoxication, unspecified
F14.250	Cocaine dependence with cocaine-induced psychotic disorder with delusions
F14.251	Cocaine dependence with cocaine-induced psychotic disorder with hallucinations
F14.259	Cocaine dependence with cocaine-induced psychotic disorder, unspecified
F14.280	Cocaine dependence with cocaine-induced anxiety disorder
F14.281	Cocaine dependence with cocaine-induced sexual dysfunction
F14.282	Cocaine dependence with cocaine-induced sleep disorder
F14.288	Cocaine dependence with other cocaine-induced disorder
F14.29	Cocaine dependence with unspecified cocaine-induced disorder
F14.90	Cocaine use, unspecified, uncomplicated

F14.920	Cocaine use, unspecified with intoxication, uncomplicated
F14.921	Cocaine use, unspecified with intoxication delirium
F14.922	Cocaine use, unspecified with intoxication with perceptual disturbance
F14.929	Cocaine use, unspecified with intoxication, unspecified
F14.94	Cocaine use, unspecified with cocaine-induced mood disorder
F14.950	Cocaine use, unspecified with cocaine-induced psychotic disorder with delusions
F14.951	Cocaine use, unspecified with cocaine-induced psychotic disorder with hallucinations
F14.959	Cocaine use, unspecified with cocaine-induced psychotic disorder, unspecified
F14.980	Cocaine use, unspecified with cocaine-induced anxiety disorder
F14.981	Cocaine use, unspecified with cocaine-induced sexual dysfunction
F14.982	Cocaine use, unspecified with cocaine-induced sleep disorder
F14.988	Cocaine use, unspecified with other cocaine-induced disorder
F14.99	Cocaine use, unspecified with unspecified cocaine-induced disorder
F15.10	Other stimulant abuse, uncomplicated
F15.11	Other stimulant abuse, in remission
F15.120	Other stimulant abuse with intoxication, uncomplicated
F15.121	Other stimulant abuse with intoxication delirium
F15.122	Other stimulant abuse with intoxication with perceptual disturbance
F15.129	Other stimulant abuse with intoxication, unspecified
F15.14	Other stimulant abuse with stimulant-induced mood disorder
F15.150	Other stimulant abuse with stimulant-induced psychotic disorder with delusions
F15.151	Other stimulant abuse with stimulant-induced psychotic disorder with hallucinations
F15.159	Other stimulant abuse with stimulant-induced psychotic disorder, unspecified
F15.180	Other stimulant abuse with stimulant-induced anxiety disorder
F15.181	Other stimulant abuse with stimulant-induced sexual dysfunction
F15.182	Other stimulant abuse with stimulant-induced sleep disorder
F15.188	Other stimulant abuse with other stimulant-induced disorder
F15.19	Other stimulant abuse with unspecified stimulant-induced disorder
F15.20	Other stimulant dependence, uncomplicated
F15.21	Other stimulant dependence, in remission
F15.220	Other stimulant dependence with intoxication, uncomplicated
F15.221	Other stimulant dependence with intoxication delirium
F15.222	Other stimulant dependence with intoxication with perceptual disturbance
F15.229	Other stimulant dependence with intoxication, unspecified
F15.23	Other stimulant dependence with withdrawal
F15.24	Other stimulant dependence with stimulant-induced mood disorder
F15.250	Other stimulant dependence with stimulant-induced psychotic disorder with delusions
F15.251	Other stimulant dependence with stimulant-induced psychotic disorder with hallucinations
F15.259	Other stimulant dependence with stimulant-induced psychotic disorder, unspecified
F15.280	Other stimulant dependence with stimulant-induced anxiety disorder
F15.281	Other stimulant dependence with stimulant-induced sexual dysfunction
F15.282	Other stimulant dependence with stimulant-induced sleep disorder
F15.288	Other stimulant dependence with other stimulant-induced disorder
F15.29	Other stimulant dependence with unspecified stimulant-induced disorder
F15.90	Other stimulant use, unspecified, uncomplicated
F15.920	Other stimulant use, unspecified with intoxication, uncomplicated
F15.921	Other stimulant use, unspecified with intoxication delirium
F15.922	Other stimulant use, unspecified with intoxication with perceptual disturbance
F15.929	Other stimulant use, unspecified with intoxication, unspecified
F15.93	Other stimulant use, unspecified with withdrawal
F15.94	Other stimulant use, unspecified with stimulant-induced mood disorder

F15.950	Other stimulant use, unspecified with stimulant-induced psychotic disorder with delusions
F15.951	Other stimulant use, unspecified with stimulant-induced psychotic disorder with hallucinations
F15.959	Other stimulant use, unspecified with stimulant-induced psychotic disorder, unspecified
F15.980	Other stimulant use, unspecified with stimulant-induced anxiety disorder
F15.981	Other stimulant use, unspecified with stimulant-induced sexual dysfunction
F15.982	Other stimulant use, unspecified with stimulant-induced sleep disorder
F15.988	Other stimulant use, unspecified with other stimulant-induced disorder
F15.99	Other stimulant use, unspecified with unspecified stimulant-induced disorder
F16.10	Hallucinogen abuse, uncomplicated
F16.11	Hallucinogen abuse, in remission
F16.120	Hallucinogen abuse with intoxication, uncomplicated
F16.121	Hallucinogen abuse with intoxication with delirium
F16.122	Hallucinogen abuse with intoxication with perceptual disturbance
F16.129	Hallucinogen abuse with intoxication, unspecified
F16.150	Hallucinogen abuse with hallucinogen-induced psychotic disorder with delusions
F16.151	Hallucinogen abuse with hallucinogen-induced psychotic disorder with hallucinations
F16.159	Hallucinogen abuse with hallucinogen-induced psychotic disorder, unspecified
F16.180	Hallucinogen abuse with hallucinogen-induced anxiety disorder
F16.183	Hallucinogen abuse with hallucinogen persisting perception disorder (flashbacks)
F16.188	Hallucinogen abuse with other hallucinogen-induced disorder
F16.19	Hallucinogen abuse with unspecified hallucinogen-induced disorder
F16.20	Hallucinogen dependence, uncomplicated
F16.21	Hallucinogen dependence, in remission
F16.220	Hallucinogen dependence with intoxication, uncomplicated
F16.221	Hallucinogen dependence with intoxication with delirium
F16.229	Hallucinogen dependence with intoxication, unspecified
F16.24	Hallucinogen dependence with hallucinogen-induced mood disorder
F16.250	Hallucinogen dependence with hallucinogen-induced psychotic disorder with delusions
F16.251	Hallucinogen dependence with hallucinogen-induced psychotic disorder with hallucinations
F16.259	Hallucinogen dependence with hallucinogen-induced psychotic disorder, unspecified
F16.280	Hallucinogen dependence with hallucinogen-induced anxiety disorder
F16.283	Hallucinogen dependence with hallucinogen persisting perception disorder (flashbacks)
F16.288	Hallucinogen dependence with other hallucinogen-induced disorder
F16.29	Hallucinogen dependence with unspecified hallucinogen-induced disorder
F16.90	Hallucinogen use, unspecified, uncomplicated
F16.920	Hallucinogen use, unspecified with intoxication, uncomplicated
F16.921	Hallucinogen use, unspecified with intoxication with delirium
F16.929	Hallucinogen use, unspecified with intoxication, unspecified
F16.94	Hallucinogen use, unspecified with hallucinogen-induced mood disorder
F16.950	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with delusions
F16.951	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder with hallucinations
F16.959	Hallucinogen use, unspecified with hallucinogen-induced psychotic disorder, unspecified
F16.980	Hallucinogen use, unspecified with hallucinogen-induced anxiety disorder
F16.983	Hallucinogen use, unspecified with hallucinogen persisting perception disorder (flashbacks)
F16.988	Hallucinogen use, unspecified with other hallucinogen-induced disorder
F16.99	Hallucinogen use, unspecified with unspecified hallucinogen-induced disorder
F18.10	Inhalant abuse, uncomplicated
F18.11	Inhalant abuse, in remission
F18.120	Inhalant abuse with intoxication, uncomplicated
F18.121	Inhalant abuse with intoxication delirium
F18.129	Inhalant abuse with intoxication, unspecified

F18.14	Inhalant abuse with inhalant-induced mood disorder
F18.150	Inhalant abuse with inhalant-induced psychotic disorder with delusions
F18.151	Inhalant abuse with inhalant-induced psychotic disorder with hallucinations
F18.159	Inhalant abuse with inhalant-induced psychotic disorder, unspecified
F18.17	Inhalant abuse with inhalant-induced dementia
F18.180	Inhalant abuse with inhalant-induced anxiety disorder
F18.188	Inhalant abuse with other inhalant-induced disorder
F18.19	Inhalant abuse with unspecified inhalant-induced disorder
F18.20	Inhalant dependence, uncomplicated
F18.21	Inhalant dependence, in remission
F18.220	Inhalant dependence with intoxication, uncomplicated
F18.221	Inhalant dependence with intoxication delirium
F18.229	Inhalant dependence with intoxication, unspecified
F18.24	Inhalant dependence with inhalant-induced mood disorder
F18.250	Inhalant dependence with inhalant-induced psychotic disorder with delusions
F18.251	Inhalant dependence with inhalant-induced psychotic disorder with hallucinations
F18.259	Inhalant dependence with inhalant-induced psychotic disorder, unspecified
F18.27	Inhalant dependence with inhalant-induced dementia
F18.280	Inhalant dependence with inhalant-induced anxiety disorder
F18.288	Inhalant dependence with other inhalant-induced disorder
F18.29	Inhalant dependence with unspecified inhalant-induced disorder
F18.90	Inhalant use, unspecified, uncomplicated
F18.920	Inhalant use, unspecified with intoxication, uncomplicated
F18.921	Inhalant use, unspecified with intoxication with delirium
F18.929	Inhalant use, unspecified with intoxication, unspecified
F18.94	Inhalant use, unspecified with inhalant-induced mood disorder
F18.950	Inhalant use, unspecified with inhalant-induced psychotic disorder with delusions
F18.951	Inhalant use, unspecified with inhalant-induced psychotic disorder with hallucinations
F18.959	Inhalant use, unspecified with inhalant-induced psychotic disorder, unspecified
F18.980	Inhalant use, unspecified with inhalant-induced anxiety disorder
F18.988	Inhalant use, unspecified with other inhalant-induced disorder
F18.99	Inhalant use, unspecified with unspecified inhalant-induced disorder
F19.10	Other psychoactive substance abuse, uncomplicated
F19.11	Other psychoactive substance abuse, in remission
F19.120	Other psychoactive substance abuse with intoxication, uncomplicated
F19.121	Other psychoactive substance abuse with intoxication delirium
F19.122	Other psychoactive substance abuse with intoxication with perceptual disturbances
F19.129	Other psychoactive substance abuse with intoxication, unspecified
F19.14	Other psychoactive substance abuse with psychoactive substance-induced mood disorder
F19.150	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with delusions
F19.151	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder with hallucinations
F19.159	Other psychoactive substance abuse with psychoactive substance-induced psychotic disorder, unspecified
F19.16	Other psychoactive substance abuse with psychoactive substance-induced persisting amnesic disorder
F19.17	Other psychoactive substance abuse with psychoactive substance-induced persisting dementia
F19.180	Other psychoactive substance abuse with psychoactive substance-induced anxiety disorder
F19.181	Other psychoactive substance abuse with psychoactive substance-induced sexual dysfunction
F19.182	Other psychoactive substance abuse with psychoactive substance-induced sleep disorder
F19.188	Other psychoactive substance abuse with other psychoactive substance-induced disorder
F19.19	Other psychoactive substance abuse with unspecified psychoactive substance-induced disorder
F19.20	Other psychoactive substance dependence, uncomplicated
F19.21	Other psychoactive substance dependence, in remission

F19.220	Other psychoactive substance dependence with intoxication, uncomplicated
F19.221	Other psychoactive substance dependence with intoxication delirium
F19.222	Other psychoactive substance dependence with intoxication with perceptual disturbance
F19.229	Other psychoactive substance dependence with intoxication, unspecified
F19.230	Other psychoactive substance dependence with withdrawal, uncomplicated
F19.231	Other psychoactive substance dependence with withdrawal delirium
F19.232	Other psychoactive substance dependence with withdrawal with perceptual disturbance
F19.239	Other psychoactive substance dependence with withdrawal, unspecified
F19.24	Other psychoactive substance dependence with psychoactive substance-induced mood disorder
F19.250	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with delusions
F19.251	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder with hallucinations
F19.259	Other psychoactive substance dependence with psychoactive substance-induced psychotic disorder, unspecified
F19.26	Other psychoactive substance dependence with psychoactive substance-induced persisting amnesic disorder
F19.27	Other psychoactive substance dependence with psychoactive substance-induced persisting dementia
F19.280	Other psychoactive substance dependence with psychoactive substance-induced anxiety disorder
F19.281	Other psychoactive substance dependence with psychoactive substance-induced sexual dysfunction
F19.282	Other psychoactive substance dependence with psychoactive substance-induced sleep disorder
F19.288	Other psychoactive substance dependence with other psychoactive substance-induced disorder
F19.29	Other psychoactive substance dependence with unspecified psychoactive substance-induced disorder
F19.90	Other psychoactive substance use, unspecified, uncomplicated
F19.920	Other psychoactive substance use, unspecified with intoxication, uncomplicated
F19.921	Other psychoactive substance use, unspecified with intoxication with delirium
F19.922	Other psychoactive substance use, unspecified with intoxication with perceptual disturbance
F19.929	Other psychoactive substance use, unspecified with intoxication, unspecified
F19.930	Other psychoactive substance use, unspecified with withdrawal, uncomplicated
F19.931	Other psychoactive substance use, unspecified with withdrawal delirium
F19.932	Other psychoactive substance use, unspecified with withdrawal with perceptual disturbance
F19.939	Other psychoactive substance use, unspecified with withdrawal, unspecified
F19.94	Other psychoactive substance use, unspecified with psychoactive substance-induced mood disorder
F19.950	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with delusions
F19.951	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder with hallucinations
F19.959	Other psychoactive substance use, unspecified with psychoactive substance-induced psychotic disorder, unspecified
F19.96	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting amnesic disorder
F19.97	Other psychoactive substance use, unspecified with psychoactive substance-induced persisting dementia
F19.980	Other psychoactive substance use, unspecified with psychoactive substance-induced anxiety disorder
F19.981	Other psychoactive substance use, unspecified with psychoactive substance-induced sexual dysfunction
F19.982	Other psychoactive substance use, unspecified with psychoactive substance-induced sleep disorder
F19.988	Other psychoactive substance use, unspecified with other psychoactive substance-induced disorder
F19.99	Other psychoactive substance use, unspecified with unspecified psychoactive substance-induced disorder
F20.0	Paranoid schizophrenia
F20.1	Disorganized schizophrenia
F20.2	Catatonic schizophrenia
F20.3	Undifferentiated schizophrenia
F20.5	Residual schizophrenia
F20.81	Schizophreniform disorder
F20.89	Other schizophrenia
F20.9	Schizophrenia, unspecified
F23	Brief psychotic disorder
F25.0	Schizoaffective disorder, bipolar type

F25.1	Schizoaffective disorder, depressive type
F25.8	Other schizoaffective disorders
F25.9	Schizoaffective disorder, unspecified
F28	Other psychotic disorder not due to a substance or known physiological condition
F29	Unspecified psychosis not due to a substance or known physiological condition
F30.10	Manic episode without psychotic symptoms, unspecified
F30.11	Manic episode without psychotic symptoms, mild
F30.12	Manic episode without psychotic symptoms, moderate
F30.13	Manic episode, severe, without psychotic symptoms
F30.2	Manic episode, severe with psychotic symptoms
F30.3	Manic episode in partial remission
F30.4	Manic episode in full remission
F30.8	Other manic episodes
F30.9	Manic episode, unspecified
F31.10	Bipolar disorder, current episode manic without psychotic features, unspecified
F31.11	Bipolar disorder, current episode manic without psychotic features, mild
F31.12	Bipolar disorder, current episode manic without psychotic features, moderate
F31.13	Bipolar disorder, current episode manic without psychotic features, severe
F31.2	Bipolar disorder, current episode manic severe with psychotic features
F31.30	Bipolar disorder, current episode depressed, mild or moderate severity, unspecified
F31.31	Bipolar disorder, current episode depressed, mild
F31.32	Bipolar disorder, current episode depressed, moderate
F31.4	Bipolar disorder, current episode depressed, severe, without psychotic features
F31.5	Bipolar disorder, current episode depressed, severe, with psychotic features
F31.60	Bipolar disorder, current episode mixed, unspecified
F31.61	Bipolar disorder, current episode mixed, mild
F31.62	Bipolar disorder, current episode mixed, moderate
F31.63	Bipolar disorder, current episode mixed, severe, without psychotic features
F31.64	Bipolar disorder, current episode mixed, severe, with psychotic features
F31.70	Bipolar disorder, currently in remission, most recent episode unspecified
F31.71	Bipolar disorder, in partial remission, most recent episode hypomanic
F31.72	Bipolar disorder, in full remission, most recent episode hypomanic
F31.73	Bipolar disorder, in partial remission, most recent episode manic
F31.74	Bipolar disorder, in full remission, most recent episode manic
F31.75	Bipolar disorder, in partial remission, most recent episode depressed
F31.76	Bipolar disorder, in full remission, most recent episode depressed
F31.77	Bipolar disorder, in partial remission, most recent episode mixed
F31.78	Bipolar disorder, in full remission, most recent episode mixed
F31.81	Bipolar II disorder
F31.89	Other bipolar disorder
F31.9	Bipolar disorder, unspecified
F32.0	Major depressive disorder, single episode, mild
F32.1	Major depressive disorder, single episode, moderate
F32.2	Major depressive disorder, single episode, severe without psychotic features
F32.3	Major depressive disorder, single episode, severe with psychotic features
F32.4	Major depressive disorder, single episode, in partial remission
F32.5	Major depressive disorder, single episode, in full remission
F32.81	Premenstrual dysphoric disorder
F32.89	Other specified depressive episodes
F32.9	Major depressive disorder, single episode, unspecified
F33.0	Major depressive disorder, recurrent, mild

F33.1	Major depressive disorder, recurrent, moderate
F33.2	Major depressive disorder, recurrent severe without psychotic features
F33.3	Major depressive disorder, recurrent, severe with psychotic symptoms
F33.40	Major depressive disorder, recurrent, in remission, unspecified
F33.41	Major depressive disorder, recurrent, in partial remission
F33.42	Major depressive disorder, recurrent, in full remission
F33.8	Other recurrent depressive disorders
F33.9	Major depressive disorder, recurrent, unspecified
F34.0	Cyclothymic disorder
F34.1	Dysthymic disorder
F34.81	Disruptive mood dysregulation disorder
F34.89	Other specified persistent mood disorders
F34.9	Persistent mood [affective] disorder, unspecified
F39	Unspecified mood [affective] disorder
F43.0	Acute stress reaction
F43.10	Post-traumatic stress disorder, unspecified
F43.11	Post-traumatic stress disorder, acute
F43.12	Post-traumatic stress disorder, chronic
F43.20	Adjustment disorder, unspecified
F43.21	Adjustment disorder with depressed mood
F43.22	Adjustment disorder with anxiety
F43.23	Adjustment disorder with mixed anxiety and depressed mood
F43.24	Adjustment disorder with disturbance of conduct
F43.25	Adjustment disorder with mixed disturbance of emotions and conduct
F43.29	Adjustment disorder with other symptoms
F43.8	Other reactions to severe stress
F43.9	Reaction to severe stress, unspecified
F44.0	Dissociative amnesia
F44.1	Dissociative fugue
F44.2	Dissociative stupor
F44.4	Conversion disorder with motor symptom or deficit
F44.5	Conversion disorder with seizures or convulsions
F44.6	Conversion disorder with sensory symptom or deficit
F44.7	Conversion disorder with mixed symptom presentation
F44.81	Dissociative identity disorder
F44.89	Other dissociative and conversion disorders
F44.9	Dissociative and conversion disorder, unspecified
F45.0	Somatization disorder
F45.1	Undifferentiated somatoform disorder
F45.20	Hypochondriacal disorder, unspecified
F45.21	Hypochondriasis
F45.22	Body dysmorphic disorder
F45.29	Other hypochondriacal disorders
F45.41	Pain disorder exclusively related to psychological factors
F45.42	Pain disorder with related psychological factors
F45.8	Other somatoform disorders
F45.9	Somatoform disorder, unspecified
F55.0	Abuse of antacids
F55.1	Abuse of herbal or folk remedies
F55.2	Abuse of laxatives
F55.3	Abuse of steroids or hormones

F55.4	Abuse of vitamins
F55.8	Abuse of other non-psychoactive substances
F60.0	Paranoid personality disorder
F60.1	Schizoid personality disorder
F60.2	Antisocial personality disorder
F60.3	Borderline personality disorder
F60.4	Histrionic personality disorder
F60.5	Obsessive-compulsive personality disorder
F60.6	Avoidant personality disorder
F60.7	Dependent personality disorder
F60.81	Narcissistic personality disorder
F60.89	Other specific personality disorders
F60.9	Personality disorder, unspecified
G40.001	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, with status epilepticus
G40.009	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, not intractable, without status epilepticus
G40.011	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, with status epilepticus
G40.019	Localization-related (focal) (partial) idiopathic epilepsy and epileptic syndromes with seizures of localized onset, intractable, without status epilepticus
G40.101	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, with status epilepticus
G40.109	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, not intractable, without status epilepticus
G40.111	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, with status epilepticus
G40.119	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with simple partial seizures, intractable, without status epilepticus
G40.201	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, with status epilepticus
G40.209	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, not intractable, without status epilepticus
G40.211	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, with status epilepticus
G40.219	Localization-related (focal) (partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures, intractable, without status epilepticus
G40.301	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, with status epilepticus
G40.309	Generalized idiopathic epilepsy and epileptic syndromes, not intractable, without status epilepticus
G40.311	Generalized idiopathic epilepsy and epileptic syndromes, intractable, with status epilepticus
G40.319	Generalized idiopathic epilepsy and epileptic syndromes, intractable, without status epilepticus
G40.A01	Absence epileptic syndrome, not intractable, with status epilepticus
G40.A09	Absence epileptic syndrome, not intractable, without status epilepticus
G40.A11	Absence epileptic syndrome, intractable, with status epilepticus
G40.A19	Absence epileptic syndrome, intractable, without status epilepticus
G40.B01	Juvenile myoclonic epilepsy, not intractable, with status epilepticus
G40.B09	Juvenile myoclonic epilepsy, not intractable, without status epilepticus
G40.B11	Juvenile myoclonic epilepsy, intractable, with status epilepticus
G40.B19	Juvenile myoclonic epilepsy, intractable, without status epilepticus
G40.401	Other generalized epilepsy and epileptic syndromes, not intractable, with status epilepticus
G40.409	Other generalized epilepsy and epileptic syndromes, not intractable, without status epilepticus
G40.411	Other generalized epilepsy and epileptic syndromes, intractable, with status epilepticus
G40.419	Other generalized epilepsy and epileptic syndromes, intractable, without status epilepticus
G40.501	Epileptic seizures related to external causes, not intractable, with status epilepticus

G40.509	Epileptic seizures related to external causes, not intractable, without status epilepticus
G40.801	Other epilepsy, not intractable, with status epilepticus
G40.802	Other epilepsy, not intractable, without status epilepticus
G40.803	Other epilepsy, intractable, with status epilepticus
G40.804	Other epilepsy, intractable, without status epilepticus
G40.811	Lennox-Gastaut syndrome, not intractable, with status epilepticus
G40.812	Lennox-Gastaut syndrome, not intractable, without status epilepticus
G40.813	Lennox-Gastaut syndrome, intractable, with status epilepticus
G40.814	Lennox-Gastaut syndrome, intractable, without status epilepticus
G40.821	Epileptic spasms, not intractable, with status epilepticus
G40.822	Epileptic spasms, not intractable, without status epilepticus
G40.823	Epileptic spasms, intractable, with status epilepticus
G40.824	Epileptic spasms, intractable, without status epilepticus
G40.89	Other seizures
G40.901	Epilepsy, unspecified, not intractable, with status epilepticus
G40.909	Epilepsy, unspecified, not intractable, without status epilepticus
G40.911	Epilepsy, unspecified, intractable, with status epilepticus
G40.919	Epilepsy, unspecified, intractable, without status epilepticus
I44.0	Atrioventricular block, first degree
I44.1	Atrioventricular block, second degree
I44.2	Atrioventricular block, complete
I44.30	Unspecified atrioventricular block
I45.81	Long QT syndrome
I47.0	Re-entry ventricular arrhythmia
I47.1	Supraventricular tachycardia
I47.2	Ventricular tachycardia
I49.2	Junctional premature depolarization
M25.50	Pain in unspecified joint
M47.811	Spondylosis without myelopathy or radiculopathy, occipito-atlanto-axial region
M47.812	Spondylosis without myelopathy or radiculopathy, cervical region
M47.813	Spondylosis without myelopathy or radiculopathy, cervicothoracic region
M47.816	Spondylosis without myelopathy or radiculopathy, lumbar region
M47.817	Spondylosis without myelopathy or radiculopathy, lumbosacral region
M47.818	Spondylosis without myelopathy or radiculopathy, sacral and sacrococcygeal region
M51.14	Intervertebral disc disorders with radiculopathy, thoracic region
M51.15	Intervertebral disc disorders with radiculopathy, thoracolumbar region
M51.16	Intervertebral disc disorders with radiculopathy, lumbar region
M51.17	Intervertebral disc disorders with radiculopathy, lumbosacral region
M51.36	Other intervertebral disc degeneration, lumbar region
M51.37	Other intervertebral disc degeneration, lumbosacral region
M54.10	Radiculopathy, site unspecified
M54.14	Radiculopathy, thoracic region
M54.15	Radiculopathy, thoracolumbar region
M54.16	Radiculopathy, lumbar region
M54.17	Radiculopathy, lumbosacral region
M54.18	Radiculopathy, sacral and sacrococcygeal region
M54.2	Cervicalgia
M54.5	Low back pain
M60.811	Other myositis, right shoulder
M60.812	Other myositis, left shoulder
M60.821	Other myositis, right upper arm

M60.822	Other myositis, left upper arm
M60.831	Other myositis, right forearm
M60.832	Other myositis, left forearm
M60.841	Other myositis, right hand
M60.842	Other myositis, left hand
M60.851	Other myositis, right thigh
M60.852	Other myositis, left thigh
M60.861	Other myositis, right lower leg
M60.862	Other myositis, left lower leg
M60.871	Other myositis, right ankle and foot
M60.872	Other myositis, left ankle and foot
M60.88	Other myositis, other site
M60.89	Other myositis, multiple sites
M79.11	Myalgia of mastication muscle
M79.12	Myalgia of auxiliary muscles, head and neck
M79.18	Myalgia, other site
M79.2	Neuralgia and neuritis, unspecified
M79.7	Fibromyalgia
R40.0	Somnolence
R40.1	Stupor
R40.2111	Coma scale, eyes open, never, in the field [EMT or ambulance]
R40.2112	Coma scale, eyes open, never, at arrival to emergency department
R40.2113	Coma scale, eyes open, never, at hospital admission
R40.2114	Coma scale, eyes open, never, 24 hours or more after hospital admission
R40.2121	Coma scale, eyes open, to pain, in the field [EMT or ambulance]
R40.2122	Coma scale, eyes open, to pain, at arrival to emergency department
R40.2123	Coma scale, eyes open, to pain, at hospital admission
R40.2124	Coma scale, eyes open, to pain, 24 hours or more after hospital admission
R40.2131	Coma scale, eyes open, to sound, in the field [EMT or ambulance]
R40.2132	Coma scale, eyes open, to sound, at arrival to emergency department
R40.2133	Coma scale, eyes open, to sound, at hospital admission
R40.2134	Coma scale, eyes open, to sound, 24 hours or more after hospital admission
R40.2141	Coma scale, eyes open, spontaneous, in the field [EMT or ambulance]
R40.2142	Coma scale, eyes open, spontaneous, at arrival to emergency department
R40.2143	Coma scale, eyes open, spontaneous, at hospital admission
R40.2144	Coma scale, eyes open, spontaneous, 24 hours or more after hospital admission
R40.2211	Coma scale, best verbal response, none, in the field [EMT or ambulance]
R40.2212	Coma scale, best verbal response, none, at arrival to emergency department
R40.2213	Coma scale, best verbal response, none, at hospital admission
R40.2214	Coma scale, best verbal response, none, 24 hours or more after hospital admission
R40.2221	Coma scale, best verbal response, incomprehensible words, in the field [EMT or ambulance]
R40.2222	Coma scale, best verbal response, incomprehensible words, at arrival to emergency department
R40.2223	Coma scale, best verbal response, incomprehensible words, at hospital admission
R40.2224	Coma scale, best verbal response, incomprehensible words, 24 hours or more after hospital admission
R40.2231	Coma scale, best verbal response, inappropriate words, in the field [EMT or ambulance]
R40.2232	Coma scale, best verbal response, inappropriate words, at arrival to emergency department
R40.2233	Coma scale, best verbal response, inappropriate words, at hospital admission
R40.2234	Coma scale, best verbal response, inappropriate words, 24 hours or more after hospital admission
R40.2241	Coma scale, best verbal response, confused conversation, in the field [EMT or ambulance]
R40.2242	Coma scale, best verbal response, confused conversation, at arrival to emergency department
R40.2243	Coma scale, best verbal response, confused conversation, at hospital admission

R40.2244	Coma scale, best verbal response, confused conversation, 24 hours or more after hospital admission
R40.2251	Coma scale, best verbal response, oriented, in the field [EMT or ambulance]
R40.2252	Coma scale, best verbal response, oriented, at arrival to emergency department
R40.2253	Coma scale, best verbal response, oriented, at hospital admission
R40.2254	Coma scale, best verbal response, oriented, 24 hours or more after hospital admission
R40.2311	Coma scale, best motor response, none, in the field [EMT or ambulance]
R40.2312	Coma scale, best motor response, none, at arrival to emergency department
R40.2313	Coma scale, best motor response, none, at hospital admission
R40.2314	Coma scale, best motor response, none, 24 hours or more after hospital admission
R40.2321	Coma scale, best motor response, extension, in the field [EMT or ambulance]
R40.2322	Coma scale, best motor response, extension, at arrival to emergency department
R40.2323	Coma scale, best motor response, extension, at hospital admission
R40.2324	Coma scale, best motor response, extension, 24 hours or more after hospital admission
R40.2331	Coma scale, best motor response, abnormal flexion, in the field [EMT or ambulance]
R40.2332	Coma scale, best motor response, abnormal flexion, at arrival to emergency department
R40.2333	Coma scale, best motor response, abnormal flexion, at hospital admission
R40.2334	Coma scale, best motor response, abnormal flexion, 24 hours or more after hospital admission
R40.2341	Coma scale, best motor response, flexion withdrawal, in the field [EMT or ambulance]
R40.2342	Coma scale, best motor response, flexion withdrawal, at arrival to emergency department
R40.2343	Coma scale, best motor response, flexion withdrawal, at hospital admission
R40.2344	Coma scale, best motor response, flexion withdrawal, 24 hours or more after hospital admission
R40.2351	Coma scale, best motor response, localizes pain, in the field [EMT or ambulance]
R40.2352	Coma scale, best motor response, localizes pain, at arrival to emergency department
R40.2353	Coma scale, best motor response, localizes pain, at hospital admission
R40.2354	Coma scale, best motor response, localizes pain, 24 hours or more after hospital admission
R40.2361	Coma scale, best motor response, obeys commands, in the field [EMT or ambulance]
R40.2362	Coma scale, best motor response, obeys commands, at arrival to emergency department
R40.2363	Coma scale, best motor response, obeys commands, at hospital admission
R40.2364	Coma scale, best motor response, obeys commands, 24 hours or more after hospital admission
R40.2410	Glasgow coma scale score 13-15, unspecified time
R40.2411	Glasgow coma scale score 13-15, in the field [EMT or ambulance]
R40.2412	Glasgow coma scale score 13-15, at arrival to emergency department
R40.2413	Glasgow coma scale score 13-15, at hospital admission
R40.2414	Glasgow coma scale score 13-15, 24 hours or more after hospital admission
R40.2420	Glasgow coma scale score 9-12, unspecified time
R40.2421	Glasgow coma scale score 9-12, in the field [EMT or ambulance]
R40.2422	Glasgow coma scale score 9-12, at arrival to emergency department
R40.2423	Glasgow coma scale score 9-12, at hospital admission
R40.2424	Glasgow coma scale score 9-12, 24 hours or more after hospital admission
R40.2430	Glasgow coma scale score 3-8, unspecified time
R40.2431	Glasgow coma scale score 3-8, in the field [EMT or ambulance]
R40.2432	Glasgow coma scale score 3-8, at arrival to emergency department
R40.2433	Glasgow coma scale score 3-8, at hospital admission
R40.2434	Glasgow coma scale score 3-8, 24 hours or more after hospital admission
R40.2440	Other coma, without documented Glasgow coma scale score, or with partial score reported, unspecified time
R40.2441	Other coma, without documented Glasgow coma scale score, or with partial score reported, in the field [EMT or ambulance]
R40.2442	Other coma, without documented Glasgow coma scale score, or with partial score reported, at arrival to emergency department
R40.2443	Other coma, without documented Glasgow coma scale score, or with partial score reported, at hospital admission
R40.2444	Other coma, without documented Glasgow coma scale score, or with partial score reported, 24 hours or more after hospital admission

R41.0	Disorientation, unspecified
R41.82	Altered mental status, unspecified
R44.0	Auditory hallucinations
R44.3	Hallucinations, unspecified
R56.00	Simple febrile convulsions
R56.01	Complex febrile convulsions
R56.1	Post traumatic seizures
R56.9	Unspecified convulsions
T39.011A	Poisoning by aspirin, accidental (unintentional), initial encounter
T39.011D	Poisoning by aspirin, accidental (unintentional), subsequent encounter
T39.012A	Poisoning by aspirin, intentional self-harm, initial encounter
T39.012D	Poisoning by aspirin, intentional self-harm, subsequent encounter
T39.013A	Poisoning by aspirin, assault, initial encounter
T39.013D	Poisoning by aspirin, assault, subsequent encounter
T39.014A	Poisoning by aspirin, undetermined, initial encounter
T39.014D	Poisoning by aspirin, undetermined, subsequent encounter
T39.015A	Adverse effect of aspirin, initial encounter
T39.015D	Adverse effect of aspirin, subsequent encounter
T39.016A	Underdosing of aspirin, initial encounter
T39.016D	Underdosing of aspirin, subsequent encounter
T39.091A	Poisoning by salicylates, accidental (unintentional), initial encounter
T39.091D	Poisoning by salicylates, accidental (unintentional), subsequent encounter
T39.092A	Poisoning by salicylates, intentional self-harm, initial encounter
T39.092D	Poisoning by salicylates, intentional self-harm, subsequent encounter
T39.093A	Poisoning by salicylates, assault, initial encounter
T39.093D	Poisoning by salicylates, assault, subsequent encounter
T39.094A	Poisoning by salicylates, undetermined, initial encounter
T39.094D	Poisoning by salicylates, undetermined, subsequent encounter
T39.095A	Adverse effect of salicylates, initial encounter
T39.095D	Adverse effect of salicylates, subsequent encounter
T39.096A	Underdosing of salicylates, initial encounter
T39.096D	Underdosing of salicylates, subsequent encounter
T39.1X1A	Poisoning by 4-Aminophenol derivatives, accidental (unintentional), initial encounter
T39.1X1D	Poisoning by 4-Aminophenol derivatives, accidental (unintentional), subsequent encounter
T39.1X2A	Poisoning by 4-Aminophenol derivatives, intentional self-harm, initial encounter
T39.1X2D	Poisoning by 4-Aminophenol derivatives, intentional self-harm, subsequent encounter
T39.1X3A	Poisoning by 4-Aminophenol derivatives, assault, initial encounter
T39.1X3D	Poisoning by 4-Aminophenol derivatives, assault, subsequent encounter
T39.1X4A	Poisoning by 4-Aminophenol derivatives, undetermined, initial encounter
T39.1X4D	Poisoning by 4-Aminophenol derivatives, undetermined, subsequent encounter
T39.1X5A	Adverse effect of 4-Aminophenol derivatives, initial encounter
T39.1X5D	Adverse effect of 4-Aminophenol derivatives, subsequent encounter
T39.1X6A	Underdosing of 4-Aminophenol derivatives, initial encounter
T39.1X6D	Underdosing of 4-Aminophenol derivatives, subsequent encounter
T39.2X1A	Poisoning by pyrazolone derivatives, accidental (unintentional), initial encounter
T39.2X1D	Poisoning by pyrazolone derivatives, accidental (unintentional), subsequent encounter
T39.2X2A	Poisoning by pyrazolone derivatives, intentional self-harm, initial encounter
T39.2X2D	Poisoning by pyrazolone derivatives, intentional self-harm, subsequent encounter
T39.2X3A	Poisoning by pyrazolone derivatives, assault, initial encounter
T39.2X3D	Poisoning by pyrazolone derivatives, assault, subsequent encounter
T39.2X4A	Poisoning by pyrazolone derivatives, undetermined, initial encounter

T39.2X4D	Poisoning by pyrazolone derivatives, undetermined, subsequent encounter
T39.2X5A	Adverse effect of pyrazolone derivatives, initial encounter
T39.2X5D	Adverse effect of pyrazolone derivatives, subsequent encounter
T39.311A	Poisoning by propionic acid derivatives, accidental (unintentional), initial encounter
T39.311D	Poisoning by propionic acid derivatives, accidental (unintentional), subsequent encounter
T39.312A	Poisoning by propionic acid derivatives, intentional self-harm, initial encounter
T39.312D	Poisoning by propionic acid derivatives, intentional self-harm, subsequent encounter
T39.313A	Poisoning by propionic acid derivatives, assault, initial encounter
T39.313D	Poisoning by propionic acid derivatives, assault, subsequent encounter
T39.314A	Poisoning by propionic acid derivatives, undetermined, initial encounter
T39.314D	Poisoning by propionic acid derivatives, undetermined, subsequent encounter
T39.315A	Adverse effect of propionic acid derivatives, initial encounter
T39.315D	Adverse effect of propionic acid derivatives, subsequent encounter
T39.316A	Underdosing of propionic acid derivatives, initial encounter
T39.316D	Underdosing of propionic acid derivatives, subsequent encounter
T39.391A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], accidental (unintentional), initial encounter
T39.391D	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], accidental (unintentional), subsequent encounter
T39.392A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, initial encounter
T39.392D	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], intentional self-harm, subsequent encounter
T39.393A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, initial encounter
T39.393D	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], assault, subsequent encounter
T39.394A	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], undetermined, initial encounter
T39.394D	Poisoning by other nonsteroidal anti-inflammatory drugs [NSAID], undetermined, subsequent encounter
T39.395A	Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
T39.395D	Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter
T39.396A	Underdosing of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter
T39.396D	Underdosing of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter
T40.0X1A	Poisoning by opium, accidental (unintentional), initial encounter
T40.0X1D	Poisoning by opium, accidental (unintentional), subsequent encounter
T40.0X2A	Poisoning by opium, intentional self-harm, initial encounter
T40.0X2D	Poisoning by opium, intentional self-harm, subsequent encounter
T40.0X3A	Poisoning by opium, assault, initial encounter
T40.0X3D	Poisoning by opium, assault, subsequent encounter
T40.0X4A	Poisoning by opium, undetermined, initial encounter
T40.0X4D	Poisoning by opium, undetermined, subsequent encounter
T40.0X5A	Adverse effect of opium, initial encounter
T40.0X5D	Adverse effect of opium, subsequent encounter
T40.0X6A	Underdosing of opium, initial encounter
T40.0X6D	Underdosing of opium, subsequent encounter
T40.1X1A	Poisoning by heroin, accidental (unintentional), initial encounter
T40.1X1D	Poisoning by heroin, accidental (unintentional), subsequent encounter
T40.1X2A	Poisoning by heroin, intentional self-harm, initial encounter
T40.1X2D	Poisoning by heroin, intentional self-harm, subsequent encounter
T40.1X3A	Poisoning by heroin, assault, initial encounter
T40.1X3D	Poisoning by heroin, assault, subsequent encounter
T40.1X4A	Poisoning by heroin, undetermined, initial encounter
T40.1X4D	Poisoning by heroin, undetermined, subsequent encounter
T40.2X1A	Poisoning by other opioids, accidental (unintentional), initial encounter
T40.2X1D	Poisoning by other opioids, accidental (unintentional), subsequent encounter
T40.2X2A	Poisoning by other opioids, intentional self-harm, initial encounter
T40.2X2D	Poisoning by other opioids, intentional self-harm, subsequent encounter

T40.2X3A	Poisoning by other opioids, assault, initial encounter
T40.2X3D	Poisoning by other opioids, assault, subsequent encounter
T40.2X4A	Poisoning by other opioids, undetermined, initial encounter
T40.2X4D	Poisoning by other opioids, undetermined, subsequent encounter
T40.2X5A	Adverse effect of other opioids, initial encounter
T40.2X5D	Adverse effect of other opioids, subsequent encounter
T40.2X6A	Underdosing of other opioids, initial encounter
T40.2X6D	Underdosing of other opioids, subsequent encounter
T40.3X1A	Poisoning by methadone, accidental (unintentional), initial encounter
T40.3X1D	Poisoning by methadone, accidental (unintentional), subsequent encounter
T40.3X2A	Poisoning by methadone, intentional self-harm, initial encounter
T40.3X2D	Poisoning by methadone, intentional self-harm, subsequent encounter
T40.3X3A	Poisoning by methadone, assault, initial encounter
T40.3X3D	Poisoning by methadone, assault, subsequent encounter
T40.3X4A	Poisoning by methadone, undetermined, initial encounter
T40.3X4D	Poisoning by methadone, undetermined, subsequent encounter
T40.3X5A	Adverse effect of methadone, initial encounter
T40.3X5D	Adverse effect of methadone, subsequent encounter
T40.3X6A	Underdosing of methadone, initial encounter
T40.3X6D	Underdosing of methadone, subsequent encounter
T40.4X1A	Poisoning by other synthetic narcotics, accidental (unintentional), initial encounter
T40.4X1D	Poisoning by other synthetic narcotics, accidental (unintentional), subsequent encounter
T40.4X2A	Poisoning by other synthetic narcotics, intentional self-harm, initial encounter
T40.4X2D	Poisoning by other synthetic narcotics, intentional self-harm, subsequent encounter
T40.4X3A	Poisoning by other synthetic narcotics, assault, initial encounter
T40.4X3D	Poisoning by other synthetic narcotics, assault, subsequent encounter
T40.4X4A	Poisoning by other synthetic narcotics, undetermined, initial encounter
T40.4X4D	Poisoning by other synthetic narcotics, undetermined, subsequent encounter
T40.4X5A	Adverse effect of other synthetic narcotics, initial encounter
T40.4X5D	Adverse effect of other synthetic narcotics, subsequent encounter
T40.4X6A	Underdosing of other synthetic narcotics, initial encounter
T40.4X6D	Underdosing of other synthetic narcotics, subsequent encounter
T40.5X1A	Poisoning by cocaine, accidental (unintentional), initial encounter
T40.5X1D	Poisoning by cocaine, accidental (unintentional), subsequent encounter
T40.5X2A	Poisoning by cocaine, intentional self-harm, initial encounter
T40.5X2D	Poisoning by cocaine, intentional self-harm, subsequent encounter
T40.5X3A	Poisoning by cocaine, assault, initial encounter
T40.5X3D	Poisoning by cocaine, assault, subsequent encounter
T40.5X4A	Poisoning by cocaine, undetermined, initial encounter
T40.5X4D	Poisoning by cocaine, undetermined, subsequent encounter
T40.5X5A	Adverse effect of cocaine, initial encounter
T40.5X5D	Adverse effect of cocaine, subsequent encounter
T40.5X6A	Underdosing of cocaine, initial encounter
T40.5X6D	Underdosing of cocaine, subsequent encounter
T40.601A	Poisoning by unspecified narcotics, accidental (unintentional), initial encounter
T40.601D	Poisoning by unspecified narcotics, accidental (unintentional), subsequent encounter
T40.602A	Poisoning by unspecified narcotics, intentional self-harm, initial encounter
T40.602D	Poisoning by unspecified narcotics, intentional self-harm, subsequent encounter
T40.603A	Poisoning by unspecified narcotics, assault, initial encounter
T40.603D	Poisoning by unspecified narcotics, assault, subsequent encounter
T40.604A	Poisoning by unspecified narcotics, undetermined, initial encounter

T40.604D	Poisoning by unspecified narcotics, undetermined, subsequent encounter
T40.605A	Adverse effect of unspecified narcotics, initial encounter
T40.605D	Adverse effect of unspecified narcotics, subsequent encounter
T40.606A	Underdosing of unspecified narcotics, initial encounter
T40.606D	Underdosing of unspecified narcotics, subsequent encounter
T40.691A	Poisoning by other narcotics, accidental (unintentional), initial encounter
T40.691D	Poisoning by other narcotics, accidental (unintentional), subsequent encounter
T40.692A	Poisoning by other narcotics, intentional self-harm, initial encounter
T40.692D	Poisoning by other narcotics, intentional self-harm, subsequent encounter
T40.693A	Poisoning by other narcotics, assault, initial encounter
T40.693D	Poisoning by other narcotics, assault, subsequent encounter
T40.694A	Poisoning by other narcotics, undetermined, initial encounter
T40.694D	Poisoning by other narcotics, undetermined, subsequent encounter
T40.695A	Adverse effect of other narcotics, initial encounter
T40.695D	Adverse effect of other narcotics, subsequent encounter
T40.696A	Underdosing of other narcotics, initial encounter
T40.696D	Underdosing of other narcotics, subsequent encounter
T40.7X1A	Poisoning by cannabis (derivatives), accidental (unintentional), initial encounter
T40.7X1D	Poisoning by cannabis (derivatives), accidental (unintentional), subsequent encounter
T40.7X2A	Poisoning by cannabis (derivatives), intentional self-harm, initial encounter
T40.7X2D	Poisoning by cannabis (derivatives), intentional self-harm, subsequent encounter
T40.7X3A	Poisoning by cannabis (derivatives), assault, initial encounter
T40.7X3D	Poisoning by cannabis (derivatives), assault, subsequent encounter
T40.7X4A	Poisoning by cannabis (derivatives), undetermined, initial encounter
T40.7X4D	Poisoning by cannabis (derivatives), undetermined, subsequent encounter
T40.7X5A	Adverse effect of cannabis (derivatives), initial encounter
T40.7X5D	Adverse effect of cannabis (derivatives), subsequent encounter
T40.7X6A	Underdosing of cannabis (derivatives), initial encounter
T40.7X6D	Underdosing of cannabis (derivatives), subsequent encounter
T40.8X1A	Poisoning by lysergide [LSD], accidental (unintentional), initial encounter
T40.8X1D	Poisoning by lysergide [LSD], accidental (unintentional), subsequent encounter
T40.8X2A	Poisoning by lysergide [LSD], intentional self-harm, initial encounter
T40.8X2D	Poisoning by lysergide [LSD], intentional self-harm, subsequent encounter
T40.8X4A	Poisoning by lysergide [LSD], undetermined, initial encounter
T40.8X4D	Poisoning by lysergide [LSD], undetermined, subsequent encounter
T40.901A	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), initial encounter
T40.901D	Poisoning by unspecified psychodysleptics [hallucinogens], accidental (unintentional), subsequent encounter
T40.902A	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, initial encounter
T40.902D	Poisoning by unspecified psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter
T40.903A	Poisoning by unspecified psychodysleptics [hallucinogens], assault, initial encounter
T40.903D	Poisoning by unspecified psychodysleptics [hallucinogens], assault, subsequent encounter
T40.904A	Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, initial encounter
T40.904D	Poisoning by unspecified psychodysleptics [hallucinogens], undetermined, subsequent encounter
T40.905A	Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter
T40.905D	Adverse effect of unspecified psychodysleptics [hallucinogens], subsequent encounter
T40.906A	Underdosing of unspecified psychodysleptics, initial encounter
T40.906D	Underdosing of unspecified psychodysleptics, subsequent encounter
T40.991A	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), initial encounter
T40.991D	Poisoning by other psychodysleptics [hallucinogens], accidental (unintentional), subsequent encounter
T40.992A	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, initial encounter
T40.992D	Poisoning by other psychodysleptics [hallucinogens], intentional self-harm, subsequent encounter

T40.993A	Poisoning by other psychodysleptics [hallucinogens], assault, initial encounter
T40.993D	Poisoning by other psychodysleptics [hallucinogens], assault, subsequent encounter
T40.994A	Poisoning by other psychodysleptics [hallucinogens], undetermined, initial encounter
T40.994D	Poisoning by other psychodysleptics [hallucinogens], undetermined, subsequent encounter
T40.995A	Adverse effect of other psychodysleptics [hallucinogens], initial encounter
T40.995D	Adverse effect of other psychodysleptics [hallucinogens], subsequent encounter
T40.996A	Underdosing of other psychodysleptics, initial encounter
T40.996D	Underdosing of other psychodysleptics, subsequent encounter
T42.0X1A	Poisoning by hydantoin derivatives, accidental (unintentional), initial encounter
T42.0X1D	Poisoning by hydantoin derivatives, accidental (unintentional), subsequent encounter
T42.0X2A	Poisoning by hydantoin derivatives, intentional self-harm, initial encounter
T42.0X2D	Poisoning by hydantoin derivatives, intentional self-harm, subsequent encounter
T42.0X3A	Poisoning by hydantoin derivatives, assault, initial encounter
T42.0X3D	Poisoning by hydantoin derivatives, assault, subsequent encounter
T42.0X4A	Poisoning by hydantoin derivatives, undetermined, initial encounter
T42.0X4D	Poisoning by hydantoin derivatives, undetermined, subsequent encounter
T42.0X5A	Adverse effect of hydantoin derivatives, initial encounter
T42.0X5D	Adverse effect of hydantoin derivatives, subsequent encounter
T42.0X6A	Underdosing of hydantoin derivatives, initial encounter
T42.0X6D	Underdosing of hydantoin derivatives, subsequent encounter
T42.3X1A	Poisoning by barbiturates, accidental (unintentional), initial encounter
T42.3X1D	Poisoning by barbiturates, accidental (unintentional), subsequent encounter
T42.3X2A	Poisoning by barbiturates, intentional self-harm, initial encounter
T42.3X2D	Poisoning by barbiturates, intentional self-harm, subsequent encounter
T42.3X3A	Poisoning by barbiturates, assault, initial encounter
T42.3X3D	Poisoning by barbiturates, assault, subsequent encounter
T42.3X4A	Poisoning by barbiturates, undetermined, initial encounter
T42.3X4D	Poisoning by barbiturates, undetermined, subsequent encounter
T42.3X5A	Adverse effect of barbiturates, initial encounter
T42.3X5D	Adverse effect of barbiturates, subsequent encounter
T42.3X6A	Underdosing of barbiturates, initial encounter
T42.3X6D	Underdosing of barbiturates, subsequent encounter
T42.4X1A	Poisoning by benzodiazepines, accidental (unintentional), initial encounter
T42.4X1D	Poisoning by benzodiazepines, accidental (unintentional), subsequent encounter
T42.4X2A	Poisoning by benzodiazepines, intentional self-harm, initial encounter
T42.4X2D	Poisoning by benzodiazepines, intentional self-harm, subsequent encounter
T42.4X3A	Poisoning by benzodiazepines, assault, initial encounter
T42.4X3D	Poisoning by benzodiazepines, assault, subsequent encounter
T42.4X4A	Poisoning by benzodiazepines, undetermined, initial encounter
T42.4X4D	Poisoning by benzodiazepines, undetermined, subsequent encounter
T42.4X5A	Adverse effect of benzodiazepines, initial encounter
T42.4X5D	Adverse effect of benzodiazepines, subsequent encounter
T42.4X6A	Underdosing of benzodiazepines, initial encounter
T42.4X6D	Underdosing of benzodiazepines, subsequent encounter
T42.6X1A	Poisoning by other antiepileptic and sedative-hypnotic drugs, accidental (unintentional), initial encounter
T42.6X1D	Poisoning by other antiepileptic and sedative-hypnotic drugs, accidental (unintentional), subsequent encounter
T42.6X2A	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter
T42.6X2D	Poisoning by other antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter
T42.6X3A	Poisoning by other antiepileptic and sedative-hypnotic drugs, assault, initial encounter
T42.6X3D	Poisoning by other antiepileptic and sedative-hypnotic drugs, assault, subsequent encounter
T42.6X4A	Poisoning by other antiepileptic and sedative-hypnotic drugs, undetermined, initial encounter

T42.6X4D	Poisoning by other antiepileptic and sedative-hypnotic drugs, undetermined, subsequent encounter
T42.6X5A	Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter
T42.6X5D	Adverse effect of other antiepileptic and sedative-hypnotic drugs, subsequent encounter
T42.6X6A	Underdosing of other antiepileptic and sedative-hypnotic drugs, initial encounter
T42.6X6D	Underdosing of other antiepileptic and sedative-hypnotic drugs, subsequent encounter
T42.71XA	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, accidental (unintentional), initial encounter
T42.71XD	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, accidental (unintentional), subsequent encounter
T42.72XA	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, initial encounter
T42.72XD	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, intentional self-harm, subsequent encounter
T42.73XA	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, assault, initial encounter
T42.73XD	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, assault, subsequent encounter
T42.74XA	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, undetermined, initial encounter
T42.74XD	Poisoning by unspecified antiepileptic and sedative-hypnotic drugs, undetermined, subsequent encounter
T42.75XA	Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
T42.75XD	Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, subsequent encounter
T42.76XA	Underdosing of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter
T42.76XD	Underdosing of unspecified antiepileptic and sedative-hypnotic drugs, subsequent encounter
T43.011A	Poisoning by tricyclic antidepressants, accidental (unintentional), initial encounter
T43.011D	Poisoning by tricyclic antidepressants, accidental (unintentional), subsequent encounter
T43.012A	Poisoning by tricyclic antidepressants, intentional self-harm, initial encounter
T43.012D	Poisoning by tricyclic antidepressants, intentional self-harm, subsequent encounter
T43.013A	Poisoning by tricyclic antidepressants, assault, initial encounter
T43.013D	Poisoning by tricyclic antidepressants, assault, subsequent encounter
T43.014A	Poisoning by tricyclic antidepressants, undetermined, initial encounter
T43.014D	Poisoning by tricyclic antidepressants, undetermined, subsequent encounter
T43.015A	Adverse effect of tricyclic antidepressants, initial encounter
T43.015D	Adverse effect of tricyclic antidepressants, subsequent encounter
T43.016A	Underdosing of tricyclic antidepressants, initial encounter
T43.016D	Underdosing of tricyclic antidepressants, subsequent encounter
T43.021A	Poisoning by tetracyclic antidepressants, accidental (unintentional), initial encounter
T43.021D	Poisoning by tetracyclic antidepressants, accidental (unintentional), subsequent encounter
T43.022A	Poisoning by tetracyclic antidepressants, intentional self-harm, initial encounter
T43.022D	Poisoning by tetracyclic antidepressants, intentional self-harm, subsequent encounter
T43.023A	Poisoning by tetracyclic antidepressants, assault, initial encounter
T43.023D	Poisoning by tetracyclic antidepressants, assault, subsequent encounter
T43.024A	Poisoning by tetracyclic antidepressants, undetermined, initial encounter
T43.024D	Poisoning by tetracyclic antidepressants, undetermined, subsequent encounter
T43.025A	Adverse effect of tetracyclic antidepressants, initial encounter
T43.025D	Adverse effect of tetracyclic antidepressants, subsequent encounter
T43.026A	Underdosing of tetracyclic antidepressants, initial encounter
T43.026D	Underdosing of tetracyclic antidepressants, subsequent encounter
T43.1X1A	Poisoning by monoamine-oxidase-inhibitor antidepressants, accidental (unintentional), initial encounter
T43.1X1D	Poisoning by monoamine-oxidase-inhibitor antidepressants, accidental (unintentional), subsequent encounter
T43.1X2A	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, initial encounter
T43.1X2D	Poisoning by monoamine-oxidase-inhibitor antidepressants, intentional self-harm, subsequent encounter
T43.1X3A	Poisoning by monoamine-oxidase-inhibitor antidepressants, assault, initial encounter
T43.1X3D	Poisoning by monoamine-oxidase-inhibitor antidepressants, assault, subsequent encounter
T43.1X4A	Poisoning by monoamine-oxidase-inhibitor antidepressants, undetermined, initial encounter
T43.1X4D	Poisoning by monoamine-oxidase-inhibitor antidepressants, undetermined, subsequent encounter
T43.1X5A	Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter
T43.1X5D	Adverse effect of monoamine-oxidase-inhibitor antidepressants, subsequent encounter

T43.1X6A	Underdosing of monoamine-oxidase-inhibitor antidepressants, initial encounter
T43.1X6D	Underdosing of monoamine-oxidase-inhibitor antidepressants, subsequent encounter
T43.201A	Poisoning by unspecified antidepressants, accidental (unintentional), initial encounter
T43.201D	Poisoning by unspecified antidepressants, accidental (unintentional), subsequent encounter
T43.202A	Poisoning by unspecified antidepressants, intentional self-harm, initial encounter
T43.202D	Poisoning by unspecified antidepressants, intentional self-harm, subsequent encounter
T43.203A	Poisoning by unspecified antidepressants, assault, initial encounter
T43.203D	Poisoning by unspecified antidepressants, assault, subsequent encounter
T43.204A	Poisoning by unspecified antidepressants, undetermined, initial encounter
T43.204D	Poisoning by unspecified antidepressants, undetermined, subsequent encounter
T43.205A	Adverse effect of unspecified antidepressants, initial encounter
T43.205D	Adverse effect of unspecified antidepressants, subsequent encounter
T43.206A	Underdosing of unspecified antidepressants, initial encounter
T43.206D	Underdosing of unspecified antidepressants, subsequent encounter
T43.211A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, accidental (unintentional), initial encounter
T43.211D	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, accidental (unintentional), subsequent encounter
T43.212A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, initial encounter
T43.212D	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, intentional self-harm, subsequent encounter
T43.213A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, assault, initial encounter
T43.213D	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, assault, subsequent encounter
T43.214A	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, undetermined, initial encounter
T43.214D	Poisoning by selective serotonin and norepinephrine reuptake inhibitors, undetermined, subsequent encounter
T43.215A	Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
T43.215D	Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, subsequent encounter
T43.216A	Underdosing of selective serotonin and norepinephrine reuptake inhibitors, initial encounter
T43.216D	Underdosing of selective serotonin and norepinephrine reuptake inhibitors, subsequent encounter
T43.221A	Poisoning by selective serotonin reuptake inhibitors, accidental (unintentional), initial encounter
T43.221D	Poisoning by selective serotonin reuptake inhibitors, accidental (unintentional), subsequent encounter
T43.222A	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, initial encounter
T43.222D	Poisoning by selective serotonin reuptake inhibitors, intentional self-harm, subsequent encounter
T43.223A	Poisoning by selective serotonin reuptake inhibitors, assault, initial encounter
T43.223D	Poisoning by selective serotonin reuptake inhibitors, assault, subsequent encounter
T43.224A	Poisoning by selective serotonin reuptake inhibitors, undetermined, initial encounter
T43.224D	Poisoning by selective serotonin reuptake inhibitors, undetermined, subsequent encounter
T43.225A	Adverse effect of selective serotonin reuptake inhibitors, initial encounter
T43.225D	Adverse effect of selective serotonin reuptake inhibitors, subsequent encounter
T43.226A	Underdosing of selective serotonin reuptake inhibitors, initial encounter
T43.226D	Underdosing of selective serotonin reuptake inhibitors, subsequent encounter
T43.291A	Poisoning by other antidepressants, accidental (unintentional), initial encounter
T43.291D	Poisoning by other antidepressants, accidental (unintentional), subsequent encounter
T43.292A	Poisoning by other antidepressants, intentional self-harm, initial encounter
T43.292D	Poisoning by other antidepressants, intentional self-harm, subsequent encounter
T43.293A	Poisoning by other antidepressants, assault, initial encounter
T43.293D	Poisoning by other antidepressants, assault, subsequent encounter
T43.294A	Poisoning by other antidepressants, undetermined, initial encounter
T43.294D	Poisoning by other antidepressants, undetermined, subsequent encounter
T43.295A	Adverse effect of other antidepressants, initial encounter
T43.295D	Adverse effect of other antidepressants, subsequent encounter
T43.296A	Underdosing of other antidepressants, initial encounter
T43.296D	Underdosing of other antidepressants, subsequent encounter

T43.3X1A	Poisoning by phenothiazine antipsychotics and neuroleptics, accidental (unintentional), initial encounter
T43.3X1D	Poisoning by phenothiazine antipsychotics and neuroleptics, accidental (unintentional), subsequent encounter
T43.3X2A	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, initial encounter
T43.3X2D	Poisoning by phenothiazine antipsychotics and neuroleptics, intentional self-harm, subsequent encounter
T43.3X3A	Poisoning by phenothiazine antipsychotics and neuroleptics, assault, initial encounter
T43.3X3D	Poisoning by phenothiazine antipsychotics and neuroleptics, assault, subsequent encounter
T43.3X4A	Poisoning by phenothiazine antipsychotics and neuroleptics, undetermined, initial encounter
T43.3X4D	Poisoning by phenothiazine antipsychotics and neuroleptics, undetermined, subsequent encounter
T43.3X5A	Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter
T43.3X5D	Adverse effect of phenothiazine antipsychotics and neuroleptics, subsequent encounter
T43.3X6A	Underdosing of phenothiazine antipsychotics and neuroleptics, initial encounter
T43.3X6D	Underdosing of phenothiazine antipsychotics and neuroleptics, subsequent encounter
T43.4X1A	Poisoning by butyrophenone and thiothixene neuroleptics, accidental (unintentional), initial encounter
T43.4X1D	Poisoning by butyrophenone and thiothixene neuroleptics, accidental (unintentional), subsequent encounter
T43.4X2A	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, initial encounter
T43.4X2D	Poisoning by butyrophenone and thiothixene neuroleptics, intentional self-harm, subsequent encounter
T43.4X3A	Poisoning by butyrophenone and thiothixene neuroleptics, assault, initial encounter
T43.4X3D	Poisoning by butyrophenone and thiothixene neuroleptics, assault, subsequent encounter
T43.4X4A	Poisoning by butyrophenone and thiothixene neuroleptics, undetermined, initial encounter
T43.4X4D	Poisoning by butyrophenone and thiothixene neuroleptics, undetermined, subsequent encounter
T43.4X5A	Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter
T43.4X5D	Adverse effect of butyrophenone and thiothixene neuroleptics, subsequent encounter
T43.4X6A	Underdosing of butyrophenone and thiothixene neuroleptics, initial encounter
T43.4X6D	Underdosing of butyrophenone and thiothixene neuroleptics, subsequent encounter
T43.501A	Poisoning by unspecified antipsychotics and neuroleptics, accidental (unintentional), initial encounter
T43.501D	Poisoning by unspecified antipsychotics and neuroleptics, accidental (unintentional), subsequent encounter
T43.502A	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, initial encounter
T43.502D	Poisoning by unspecified antipsychotics and neuroleptics, intentional self-harm, subsequent encounter
T43.503A	Poisoning by unspecified antipsychotics and neuroleptics, assault, initial encounter
T43.503D	Poisoning by unspecified antipsychotics and neuroleptics, assault, subsequent encounter
T43.504A	Poisoning by unspecified antipsychotics and neuroleptics, undetermined, initial encounter
T43.504D	Poisoning by unspecified antipsychotics and neuroleptics, undetermined, subsequent encounter
T43.505A	Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter
T43.505D	Adverse effect of unspecified antipsychotics and neuroleptics, subsequent encounter
T43.506A	Underdosing of unspecified antipsychotics and neuroleptics, initial encounter
T43.506D	Underdosing of unspecified antipsychotics and neuroleptics, subsequent encounter
T43.591A	Poisoning by other antipsychotics and neuroleptics, accidental (unintentional), initial encounter
T43.591D	Poisoning by other antipsychotics and neuroleptics, accidental (unintentional), subsequent encounter
T43.592A	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, initial encounter
T43.592D	Poisoning by other antipsychotics and neuroleptics, intentional self-harm, subsequent encounter
T43.593A	Poisoning by other antipsychotics and neuroleptics, assault, initial encounter
T43.593D	Poisoning by other antipsychotics and neuroleptics, assault, subsequent encounter
T43.594A	Poisoning by other antipsychotics and neuroleptics, undetermined, initial encounter
T43.594D	Poisoning by other antipsychotics and neuroleptics, undetermined, subsequent encounter
T43.595A	Adverse effect of other antipsychotics and neuroleptics, initial encounter
T43.595D	Adverse effect of other antipsychotics and neuroleptics, subsequent encounter
T43.596A	Underdosing of other antipsychotics and neuroleptics, initial encounter
T43.596D	Underdosing of other antipsychotics and neuroleptics, subsequent encounter
T43.601A	Poisoning by unspecified psychostimulants, accidental (unintentional), initial encounter
T43.601D	Poisoning by unspecified psychostimulants, accidental (unintentional), subsequent encounter
T43.602A	Poisoning by unspecified psychostimulants, intentional self-harm, initial encounter

T43.602D	Poisoning by unspecified psychostimulants, intentional self-harm, subsequent encounter
T43.603A	Poisoning by unspecified psychostimulants, assault, initial encounter
T43.603D	Poisoning by unspecified psychostimulants, assault, subsequent encounter
T43.604A	Poisoning by unspecified psychostimulants, undetermined, initial encounter
T43.604D	Poisoning by unspecified psychostimulants, undetermined, subsequent encounter
T43.605A	Adverse effect of unspecified psychostimulants, initial encounter
T43.605D	Adverse effect of unspecified psychostimulants, subsequent encounter
T43.606A	Underdosing of unspecified psychostimulants, initial encounter
T43.606D	Underdosing of unspecified psychostimulants, subsequent encounter
T43.611A	Poisoning by caffeine, accidental (unintentional), initial encounter
T43.611D	Poisoning by caffeine, accidental (unintentional), subsequent encounter
T43.612A	Poisoning by caffeine, intentional self-harm, initial encounter
T43.612D	Poisoning by caffeine, intentional self-harm, subsequent encounter
T43.613A	Poisoning by caffeine, assault, initial encounter
T43.613D	Poisoning by caffeine, assault, subsequent encounter
T43.614A	Poisoning by caffeine, undetermined, initial encounter
T43.614D	Poisoning by caffeine, undetermined, subsequent encounter
T43.615A	Adverse effect of caffeine, initial encounter
T43.615D	Adverse effect of caffeine, subsequent encounter
T43.616A	Underdosing of caffeine, initial encounter
T43.616D	Underdosing of caffeine, subsequent encounter
T43.621A	Poisoning by amphetamines, accidental (unintentional), initial encounter
T43.621D	Poisoning by amphetamines, accidental (unintentional), subsequent encounter
T43.622A	Poisoning by amphetamines, intentional self-harm, initial encounter
T43.622D	Poisoning by amphetamines, intentional self-harm, subsequent encounter
T43.623A	Poisoning by amphetamines, assault, initial encounter
T43.623D	Poisoning by amphetamines, assault, subsequent encounter
T43.624A	Poisoning by amphetamines, undetermined, initial encounter
T43.624D	Poisoning by amphetamines, undetermined, subsequent encounter
T43.625A	Adverse effect of amphetamines, initial encounter
T43.625D	Adverse effect of amphetamines, subsequent encounter
T43.626A	Underdosing of amphetamines, initial encounter
T43.626D	Underdosing of amphetamines, subsequent encounter
T43.631A	Poisoning by methylphenidate, accidental (unintentional), initial encounter
T43.631D	Poisoning by methylphenidate, accidental (unintentional), subsequent encounter
T43.632A	Poisoning by methylphenidate, intentional self-harm, initial encounter
T43.632D	Poisoning by methylphenidate, intentional self-harm, subsequent encounter
T43.633A	Poisoning by methylphenidate, assault, initial encounter
T43.633D	Poisoning by methylphenidate, assault, subsequent encounter
T43.634A	Poisoning by methylphenidate, undetermined, initial encounter
T43.634D	Poisoning by methylphenidate, undetermined, subsequent encounter
T43.635A	Adverse effect of methylphenidate, initial encounter
T43.635D	Adverse effect of methylphenidate, subsequent encounter
T43.636A	Underdosing of methylphenidate, initial encounter
T43.636D	Underdosing of methylphenidate, subsequent encounter
T43.641A	Poisoning by ecstasy, accidental (unintentional), initial encounter
T43.641D	Poisoning by ecstasy, accidental (unintentional), subsequent encounter
T43.642A	Poisoning by ecstasy, intentional self-harm, initial encounter
T43.642D	Poisoning by ecstasy, intentional self-harm, subsequent encounter
T43.643A	Poisoning by ecstasy, assault, initial encounter
T43.643D	Poisoning by ecstasy, assault, subsequent encounter

T43.644A	Poisoning by ecstasy, undetermined, initial encounter
T43.644D	Poisoning by ecstasy, undetermined, subsequent encounter
T43.691A	Poisoning by other psychostimulants, accidental (unintentional), initial encounter
T43.691D	Poisoning by other psychostimulants, accidental (unintentional), subsequent encounter
T43.692A	Poisoning by other psychostimulants, intentional self-harm, initial encounter
T43.692D	Poisoning by other psychostimulants, intentional self-harm, subsequent encounter
T43.693A	Poisoning by other psychostimulants, assault, initial encounter
T43.693D	Poisoning by other psychostimulants, assault, subsequent encounter
T43.694A	Poisoning by other psychostimulants, undetermined, initial encounter
T43.694D	Poisoning by other psychostimulants, undetermined, subsequent encounter
T43.695A	Adverse effect of other psychostimulants, initial encounter
T43.695D	Adverse effect of other psychostimulants, subsequent encounter
T43.696A	Underdosing of other psychostimulants, initial encounter
T43.696D	Underdosing of other psychostimulants, subsequent encounter
T43.8X1A	Poisoning by other psychotropic drugs, accidental (unintentional), initial encounter
T43.8X1D	Poisoning by other psychotropic drugs, accidental (unintentional), subsequent encounter
T43.8X2A	Poisoning by other psychotropic drugs, intentional self-harm, initial encounter
T43.8X2D	Poisoning by other psychotropic drugs, intentional self-harm, subsequent encounter
T43.8X3A	Poisoning by other psychotropic drugs, assault, initial encounter
T43.8X3D	Poisoning by other psychotropic drugs, assault, subsequent encounter
T43.8X4A	Poisoning by other psychotropic drugs, undetermined, initial encounter
T43.8X4D	Poisoning by other psychotropic drugs, undetermined, subsequent encounter
T43.8X5A	Adverse effect of other psychotropic drugs, initial encounter
T43.8X5D	Adverse effect of other psychotropic drugs, subsequent encounter
T43.8X6A	Underdosing of other psychotropic drugs, initial encounter
T43.8X6D	Underdosing of other psychotropic drugs, subsequent encounter
T43.91XA	Poisoning by unspecified psychotropic drug, accidental (unintentional), initial encounter
T43.91XD	Poisoning by unspecified psychotropic drug, accidental (unintentional), subsequent encounter
T43.92XA	Poisoning by unspecified psychotropic drug, intentional self-harm, initial encounter
T43.92XD	Poisoning by unspecified psychotropic drug, intentional self-harm, subsequent encounter
T43.93XA	Poisoning by unspecified psychotropic drug, assault, initial encounter
T43.93XD	Poisoning by unspecified psychotropic drug, assault, subsequent encounter
T43.94XA	Poisoning by unspecified psychotropic drug, undetermined, initial encounter
T43.94XD	Poisoning by unspecified psychotropic drug, undetermined, subsequent encounter
T43.95XA	Adverse effect of unspecified psychotropic drug, initial encounter
T43.95XD	Adverse effect of unspecified psychotropic drug, subsequent encounter
T43.96XA	Underdosing of unspecified psychotropic drug, initial encounter
T43.96XD	Underdosing of unspecified psychotropic drug, subsequent encounter
T45.0X1A	Poisoning by antiallergic and antiemetic drugs, accidental (unintentional), initial encounter
T45.0X1D	Poisoning by antiallergic and antiemetic drugs, accidental (unintentional), subsequent encounter
T45.0X2A	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, initial encounter
T45.0X2D	Poisoning by antiallergic and antiemetic drugs, intentional self-harm, subsequent encounter
T45.0X3A	Poisoning by antiallergic and antiemetic drugs, assault, initial encounter
T45.0X3D	Poisoning by antiallergic and antiemetic drugs, assault, subsequent encounter
T45.0X4A	Poisoning by antiallergic and antiemetic drugs, undetermined, initial encounter
T45.0X4D	Poisoning by antiallergic and antiemetic drugs, undetermined, subsequent encounter
T45.0X5A	Adverse effect of antiallergic and antiemetic drugs, initial encounter
T45.0X5D	Adverse effect of antiallergic and antiemetic drugs, subsequent encounter
T45.0X6A	Underdosing of antiallergic and antiemetic drugs, initial encounter
T45.0X6D	Underdosing of antiallergic and antiemetic drugs, subsequent encounter
T46.0X1A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, accidental (unintentional), initial encounter

T46.0X1D	Poisoning by cardiac-stimulant glycosides and drugs of similar action, accidental (unintentional), subsequent encounter
T46.0X2A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, initial encounter
T46.0X2D	Poisoning by cardiac-stimulant glycosides and drugs of similar action, intentional self-harm, subsequent encounter
T46.0X3A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, assault, initial encounter
T46.0X3D	Poisoning by cardiac-stimulant glycosides and drugs of similar action, assault, subsequent encounter
T46.0X4A	Poisoning by cardiac-stimulant glycosides and drugs of similar action, undetermined, initial encounter
T46.0X4D	Poisoning by cardiac-stimulant glycosides and drugs of similar action, undetermined, subsequent encounter
T46.0X5A	Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter
T46.0X5D	Adverse effect of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter
T46.0X6A	Underdosing of cardiac-stimulant glycosides and drugs of similar action, initial encounter
T46.0X6D	Underdosing of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter
T50.901A	Poisoning by unspecified drugs, medicaments and biological substances, accidental (unintentional), initial encounter
T50.901D	Poisoning by unspecified drugs, medicaments and biological substances, accidental (unintentional), subsequent encounter
T50.902A	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, initial encounter
T50.902D	Poisoning by unspecified drugs, medicaments and biological substances, intentional self-harm, subsequent encounter
T50.903A	Poisoning by unspecified drugs, medicaments and biological substances, assault, initial encounter
T50.903D	Poisoning by unspecified drugs, medicaments and biological substances, assault, subsequent encounter
T50.904A	Poisoning by unspecified drugs, medicaments and biological substances, undetermined, initial encounter
T50.904D	Poisoning by unspecified drugs, medicaments and biological substances, undetermined, subsequent encounter
T50.905A	Adverse effect of unspecified drugs, medicaments and biological substances, initial encounter
T50.905D	Adverse effect of unspecified drugs, medicaments and biological substances, subsequent encounter
T50.906A	Underdosing of unspecified drugs, medicaments and biological substances, initial encounter
T50.906D	Underdosing of unspecified drugs, medicaments and biological substances, subsequent encounter
T50.991A	Poisoning by other drugs, medicaments and biological substances, accidental (unintentional), initial encounter
T50.991D	Poisoning by other drugs, medicaments and biological substances, accidental (unintentional), subsequent encounter
T50.992A	Poisoning by other drugs, medicaments and biological substances, intentional self-harm, initial encounter
T50.992D	Poisoning by other drugs, medicaments and biological substances, intentional self-harm, subsequent encounter
T50.993A	Poisoning by other drugs, medicaments and biological substances, assault, initial encounter
T50.993D	Poisoning by other drugs, medicaments and biological substances, assault, subsequent encounter
T50.994A	Poisoning by other drugs, medicaments and biological substances, undetermined, initial encounter
T50.994D	Poisoning by other drugs, medicaments and biological substances, undetermined, subsequent encounter
T50.995A	Adverse effect of other drugs, medicaments and biological substances, initial encounter
T50.995D	Adverse effect of other drugs, medicaments and biological substances, subsequent encounter
T50.996A	Underdosing of other drugs, medicaments and biological substances, initial encounter
T50.996D	Underdosing of other drugs, medicaments and biological substances, subsequent encounter
Z71.51 *	Drug abuse counseling and surveillance of drug abuser
Z79.891 *	Long term (current) use of opiate analgesic
Z79.899	Other long term (current) drug therapy
Z91.120	Patient's intentional underdosing of medication regimen due to financial hardship
Z91.128	Patient's intentional underdosing of medication regimen for other reason
Z91.130	Patient's unintentional underdosing of medication regimen due to age-related debility
Z91.138	Patient's unintentional underdosing of medication regimen for other reason
Z91.14	Patient's other noncompliance with medication regimen
Z91.19	Patient's noncompliance with other medical treatment and regimen

\*Use ICD-10-CM code Z71.51 as the primary diagnosis and the specific drug dependence diagnosis as the secondary diagnosis.

\*Use ICD-10-CM code Z79.891 for COT monitoring.

## Associated Information

### Documentation Requirements

1. All documentation must be maintained in the patient's medical record and made available to the contractor upon request.
2. Every page of the record must be legible and include appropriate patient identification information (e.g., complete name, dates of service[s]). The documentation must include the legible signature of the physician or non-physician practitioner responsible for and providing the care to the patient.
3. The submitted medical record must support the use of the selected ICD-10-CM code(s). The submitted CPT/HCPCS code must describe the service performed.
4. The medical record documentation must support the medical necessity of the services as stated in this policy.
5. Medical record documentation (e.g., history and physical, progress notes) maintained by the ordering physician/treating physician must indicate the medical necessity for performing a qualitative drug test. All tests must be ordered in writing by the treating provider and all drugs/drug classes to be tested must be indicated in the order.
6. When a definitive/quantitative test is performed, the record must show that an inconsistent positive finding was noted on the presumptive testing or that there was no available, commercially or otherwise, presumptive test except when not medically necessary to perform presumptive testing in the COT patient subset.
7. If the provider of the service is other than the ordering/referring physician, that provider must maintain hard copy documentation of the lab results, along with copies of the ordering/referring physician's order for the test. The physician must include the clinical indication/medical necessity in the order for the test.

### Utilization Guidelines

In accordance with CMS Ruling 95-1 (V), utilization of these services should be consistent with locally acceptable standards of practice.

1. The contractor will consider presumptive UDT testing in excess of 12 per Calendar year not reasonable and necessary.

**NOTE:** An exception to the above limitation will be made when patients have documented diagnoses consistent with a substance abuse disorder (SUD), for which patients presumptive UDT shall not occur more than 3 times within a seven-day period, based upon the following guidelines for monitoring abstinence.

- For patients with 0 to 30 consecutive days of abstinence, presumptive UDT is expected at a frequency of 1 to 3 presumptive UDT per week. More than 3 presumptive panels in one week is not reasonable and necessary and is not covered by Medicare.
  - For patients with 31 to 90 consecutive days of abstinence, presumptive UDT is expected at a frequency of 1 to 3 UDT per week. More than 3 presumptive UDT in one week is not reasonable and necessary and is not covered by Medicare.
  - For patients with more than 90 consecutive days of abstinence, presumptive UDT is expected at a frequency of 1 to 3 UDT in one month. More than 3 physician-directed UDT in one month is not reasonable and necessary and is not covered by Medicare.
2. The contractor will only pay for one presumptive UDT test per patient per date of service regardless of the number of billing providers.
  3. For chronic opioid therapy (COT), the contractor will consider up to 12 definitive tests (i.e., definitive UDT) per Calendar year reasonable and necessary. This would correspond to random testing performed 1-3 times every 3 months for prescribed medications, non-prescribed medications that may pose a safety risk if mixed with prescribed and illicit substances based on patient history, clinical presentation or community usage.

### Sources of Information and Basis for Decision

**Contractor is not responsible for the continued viability of websites listed.**

AMA Report 2 of the Council on Science and Public Health (I-08): Improving Medical Practice and Patient/Family Education to Reverse the Epidemic of Nonmedical Prescription Drug Use and Addiction. <http://www.ama-assn.org/resources/doc/csaph/csaph2i08.pdf>

American Academy of Pain Medicine, Guideline Statement, Use of Opioids for the Treatment of Chronic Pain, March 2013, available online at <http://www.painmed.org/files/use-of-opioids-for-the-treatment-of-chronic-pain.pdf>.

Barthwell A. Principles for Urine Drug Testing in Addiction Medicine. CLAAD June 23, 2014. <http://claad.org/principles-for-urine-drug-testing-in-addiction-medicine/>

Bolen J., Survey of Drug Testing Policy in the Management of Chronic Pain, *J. Opioid Management*, 2014.

CDC Congressional Testimony. March 12, 2008. United States Senate Subcommittee on Crime & Drugs. Committee on the Judiciary and the Caucus on International Narcotics Control. 2009; 58:42.

Centers for Disease Control and Prevention. Unintentional Drug Poisoning in the United States.

July 2010. <http://www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdf>

Centers for Disease Control: Policy Impact: Prescription Painkiller Overdose Deaths. July 2013. Available online at <http://www.cdc.gov/HomeandRecreationalSafety/pdf/PolicyImpact-PrescriptionPainkillerOD.pdf>.

Chou R, Fanciullo GJ. Opioid Treatment Guidelines; Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. *J Pain*. 2009; 10(2): 113-130.

Department of Health and Human Services. Morbidity and Mortality Weekly Report. Overdose deaths involving prescription opioids among enrollees- Washington, 2004-2007. Available at <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5842a1.htm>

DuPont RL, Shea CL, Barthwell AG, et al. Drug Testing: A White Paper of the American Society of Addiction Medicine (ASAM). American Society of Addiction Medicine. White Paper. 2013.

Federation of State Medical Boards (FSMB), Model Policy for the Use of Opioid Analgesics for the Treatment of Chronic Pain, July 2013, available online at [http://www.fsmb.org/pdf/pain\\_policy\\_july2013.pdf](http://www.fsmb.org/pdf/pain_policy_july2013.pdf).

Gourlay DL, Caplan YH. Urine Drug testing in Clinical Practice. [http://www.familydocs.org/files/UDTMonograph\\_for\\_web.pdf](http://www.familydocs.org/files/UDTMonograph_for_web.pdf).

[http://www.toxicologyunit.com/drug\\_screen.htm](http://www.toxicologyunit.com/drug_screen.htm) retrieved from internet September 2, 2009. Institute for Clinical Systems Improvement (ICSI). Guideline for the assessment and management of chronic pain. November 2011. [http://www.icsi.org/pain\\_chronic\\_assessment\\_and\\_management\\_of\\_14399/pain\\_chronic\\_assessment\\_and\\_management\\_of\\_guideline\\_.html](http://www.icsi.org/pain_chronic_assessment_and_management_of_14399/pain_chronic_assessment_and_management_of_guideline_.html)

Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain: An educational aid to improve care and safety with opioid therapy 2010 Update; <http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf>.

Jackman RP, Purvis JM. Chronic Nonmalignant Pain in Primary Care. *American Family Physician*. 2008; 78(10):1155-1162.

Jamison RN, Ross EL, Michna E, Chen LQ, Holcomb C, Wasan AD. Substance misuse treatment for high-risk chronic pain patients on opioid therapy: a randomized trial. *Pain*. 2010; 150(3):390-400.

Jones T and Moore TM. Preliminary Data on a New Risk Assessment Tool: The Brief Risk Interview. *Journal of Opioid Management*. 2013;9 (1): 19-27.

Jones T and Passik SD. "A Comparison of Methods of Administering the Opioid Risk Tool." *Journal of Opioid Management*. 2011;7(5):347-352.

Jones T, McCoy D, Moore TM, Browder, JH, and Daffron S. "Urine Drug Testing as an Evaluation of Risk Management Strategies," *Practical Pain Management*. 2010;10(5):26-30.

Jones T, Moore T, et al. A comparison of various risk screening methods in predicting discharge from opioid treatment. *Clin J Pain*. 2012;28(2):93-100.

Jones T, Moore TM, Levy J, Browder JH, Daffron S, and Passik SD. "A Comparison of Various Risk Screening Methods for Patients Receiving Opioids for Chronic Pain Management." *Clinical Journal of Pain*. 2012;28(2):93-100.

Mallya A., Purnell AL, Svrakic DM, et al. Witnesses versus unwitnessed random urine tests in the treatment of opioid dependence. *Am J Addict*. 2013; 22(2):175-177.

Melanson Stacy EF, Baskin LB. Interpretation and utility of drug of abuse immunoassays:

lessons from laboratory drug testing surveys. *Arch Pathol Lab Med.* 2010;134:736-739.

Michna, E. et al. Urine toxicology screening among chronic pain patients of opioid therapy: frequency and predictability of abnormal findings. *Clin J Pain.* 2007;23(2):173- 179.

Moore TM, Jones T, et al. A comparison of common screening methods for predicting aberrant drug-related behavior among patients receiving opioids for chronic pain management. *Pain Med.* 2009;10:1426-1433.

Nafziger AN, Bertino JS. Utility and application of urine drug testing in chronic pain management with opioids. *Clin J Pain.* 2009;25(1)73-79.

Nicholson B, Passik S. Management of chronic non-cancer pain in the primary care setting. *SMJ.* 2007;100(10):1028-1034.

Passik S and Jones T. "Risk Assessment 2.0." *PainWeek Journal.* 2013;1(3):5-9.

Passik SD, Kirsh KL, Casper D. Addiction-related assessment tools and pain management: instruments for screening, treatment planning and monitoring compliance. *Pain Med.* 2008;9:S145-S166.

Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. *Mayo Clinic Proceedings.* 2009;84(7):593-601.

Reisfield GM, Wasan AD, Jamison RN. The prevalence and significance of cannabis uses in patients prescribed chronic opioid therapy: a review of the extant literature. *Pain Med.* 2009; 10(8):1434-1441.

SAMHSA, Clinical Drug Testing in Primary Care, Rockville, MD: SAMHSA; 2012. Technical Assistance Publication (TAP) 32, HHS publication (SMA) 12-4668, available online at <http://store.samhsa.gov/product/TAP-32-Clinical-Drug-Testing-in-Primary-Care/SMA12-4668>.

Schneider J, Miller A. Urine drug tests in a private chronic pain practice. *PPM.* January/February 2008. <http://www.tufts.edu/data/41/528854.pdf>.

Standridge JB, Adams SM. Urine drug screening: a valuable office procedure. *American Family Physician.* 2010;81(5):635-640.

Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. *Ann Intern Med.* 2010; 152(11):712-720.

Trescot AM, Standiford H. Opioids in the management of chronic non-cancer pain: an update on American Society of the Interventional Pain Physicians' (ASIPP) guidelines. *AFP.* 2008;11:S5-S61.

University of Washington, Division of Pain Medicine, Urine Drug Testing Interpretive Algorithm for Monitoring Opioid Treatment (adapted from the Washington Agency Medical Directors Group Opioid Treatment Guidelines 2010), available online At <http://depts.washington.edu/anesth/education/forms/pain/UWUDTinterpretationAlgorithm.pdf>

US Food & Drug Administration, Goal of Labeling Changes: Better Prescribing, Safer Use of Opioids, Sept. 2013, available online at <http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm367660.htm>.

Other Contractor Policies

Palmetto GBA LCD, L35105, Controlled Substance Monitoring and Drugs of Abuse Testing

JL ICD-9 LCD L32050, Qualitative Drug Testing

**Start Date of Notice Period** 11/05/2015

Revision History Information		
Revision History Date	Revision History Number	Revision History Explanation
10/01/2018	R16	<p>LCD revised and published on 10/25/2018 effective for dates of service on and after 10/01/2018 to reflect the ICD-10-CM Annual Code Updates. The following ICD-10-CM code(s) have been deleted and therefore removed from Group 1 and Group 2 Codes of the LCD: M79.1. The following ICD-10-CM code(s) have been added to Group 1 Codes: M79.11, M79.12, M79.18, T43.641A, T43.642A, T43.643A, T43.644A. The following ICD-10-CM code(s) have been added to Group 2 Codes: F12.23, F12.93, M79.11, M79.12, M79.18, T43.641A, T43.641D, T43.642A, T43.642D, T43.643A, T43.643D, T43.644A, T43.644D. The following ICD-10-CM code(s) have undergone a descriptor change: R40.2331, R40.2332, R40.2333, R40.2334. Documentation Requirement #4 updated with standard policy language.</p> <p>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; therefore, not all the fields included on the LCD are applicable as noted in this policy.</p>
03/08/2018	R15	<p>LCD revised and published on 03/08/2018 to remove Bill Type 21x as that Bill Type is not for inpatient services claims; and to add an asterisk to the Group 1 Medical Necessity ICD-10 Codes Asterisk Explanation area. Statement that physicians are to select the most appropriate diagnosis code as labs are not to prepopulate requisition forms with diagnosis codes relocated from the Group 1 and 2 Asterisk Explanation areas to the Group 1 and 2 Paragraphs.</p> <p>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; therefore, not all the fields included on the LCD are applicable as noted in this policy.</p>
02/08/2018	R14	<p>LCD revised and published on 02/08/2018 effective for dates of service on and after 11/07/2017 to remove the following CPT codes from Group 2 codes: 80159, 80171, 80173, 80183, 80184, 83789, 83992, 84999. These CPT codes for individual drugs have been removed as the HCPCS codes for definitive drug testing incorporate all classes of drugs.</p> <p>At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; therefore, not all the fields included on the LCD are applicable as noted in this policy.</p>

01/01/2018 R13 LCD revised and published on 01/25/2018 effective for dates of service on and after 01/01/2018 to reflect the annual CPT/HCPCS code updates. For the following CPT/HCPCS codes either the short description and/or the long description was changed: 80305, 80306, 80307. Depending on which description is used in this LCD there may not be any change in how the code displays in the document.

At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; therefore, not all the fields included on the LCD are applicable as noted in this policy.

10/01/2017 R12 LCD revised and published on 10/05/2017 effective for dates of service on and after 10/01/2017 to reflect the ICD-10 Annual Code Updates. The following ICD-10 code(s) have been added to Group 2 Codes: F10.11, F11.11, F12.11, F13.11, F14.11, F15.11, F16.11, F18.11, F19.11.

At this time 21st Century Cures Act will apply to new and revised LCDs that restrict coverage which requires comment and notice. This revision is not a restriction to the coverage determination; therefore, not all the fields included on the LCD are applicable as noted in this policy.

01/01/2017 R11 LCD updated on 03/16/2017 to add HCPCS code G0659 to the CPT/HCPCS Group 2 list and to remove the following statement from the Group 2 Paragraph section: "Note: HCPCS code G0659 (Drug test def simple all cl) is hereby added to the Group 2 codes below effective for dates of service on or after 1/01/2017."

01/01/2017 R10 LCD revised and published on 01/12/2017 effective for dates of service on and after 01/01/2017 to reflect the annual CPT/HCPCS code updates. The following CPT/HCPCS codes G0477, G0478, and G0479 have been deleted and therefore removed from group 1 of the LCD. The following CPT/HCPCS codes 80305, 80306, and 80307 have been added to group 1; CPT/HCPCS code G0659 has been added to group 2 of the LCD. For the following CPT/HCPCS codes either the short description and/or the long description was changed. Depending on which description is used in this LCD there may not be any change in how the code displays in the document: G0480, G0481, G0482, and G0483.

10/01/2016 R9 LCD revised and published on 09/29/2016 effective for dates of service on and after 10/01/2016 to reflect the ICD-10 Annual Code Updates. The following ICD-10 codes have been deleted and therefore removed from the Group 2 list of the ICD-10 codes in the LCD: F32.8 and F34.8. The following ICD-10 codes have been added to the list of Group 1 diagnosis codes: R40.2410, R240.2411, R40.2412, R40.2413, R40.2414, R40.2420, R40.2421, R40.2422, R40.2423, R40.2424, R240.2430, R40.2431, R40.2432, R40.2433, R40.2434, R40.2440, R40.2441, R40.2442, R40.2443 and R40.2444. The following ICD-10 codes have been added to Group 2 diagnosis codes: F32.81, F32.89, F34.81, F34.89, R40.2410, R40.2411, R40.2412, R40.2413, R40.2414, R40.2420, R40.2421, R40.2422, R40.2423, R40.2424, R240.2430, R40.2431, R40.2432, R40.2433, R40.2434, R40.2440, R40.2441, R40.2442, R40.2443 and R40.2444.

01/01/2016 R8 LCD revised and published on 02/19/16 effective for dates of service on or after 01/01/2016. New CPT/HCPCS codes added to the LCD on 12/31/15 in response to the 2016 annual CPT/HCPCS update have been placed into the appropriate CPT/HCPCS group 1 and group 2 coding sections. Language in CPT/HCPCS Group 1 Paragraph that was added on 12/31/15 has been deleted. Please refer to revision history R7 for detailed information regarding the code changes.

12/31/2015	R7	12/31/15 LCD revised to add the following ICD-10-CM codes to the ICD-10 code group 1 and group 2 as covered diagnoses: Z71.51*; Z91.120; Z91.128; Z91.130; Z91.138; Z91.14; Z91.19; Z79.891; Z79.899 effective for dates of service on and after 12/31/15. The following CPT/HCPCS codes have been added to the CPT/HCPCS code group 1 paragraph and will become group 1 codes effective for dates of service on or after 01/01/2016 to reflect the 2016 annual CPT/HCPCS update; G0477; G0478 and G0479. The following CPT/HCPCS codes will be deleted from the CPT/HCPCS code group 1 effective for dates of service on or after 01/01/2016 as a result of the 2016 annual code update; G0431 and G0434. The following CPT/HCPCS codes have been added to the group 1 paragraph and will become group 2 codes effective for dates of service on or after 01/01/2016 to reflect the 2016 annual CPT/HCPCS update; G04080; G0481; G0482 and G0483. The following CPT/HCPCS codes will be deleted from the CPT/HCPCS group 2 (currently listed in the group 1 paragraph) effective for dates of service on or after 01/01/2016 as a result of the 2016 annual code update; G6030; G6031; G6032; G6034; G6036; G6037; G6040; G6041; G6042; G6043; G6044; G6045; G6046; G6048; G6051; G6052; G6053; G6056; G6057; G6058.
12/31/2015	R6	LCD posted for notice on 11/05/2015 to become effective 12/31/2015.  05/14/2015 Draft LCD posted for comment.
10/01/2015	R5	LCD revised and published 10/29/2015 to add additional ICD-10 codes with higher specificity effective for dates of service 10/01/2015 and after.
10/01/2015	R4	LCD published 01/23/2015 to correct the publication date of the annual CPT/HCPCS code updates incorrectly listed as 01/22/2015 in revision history below. The code updates remain as listed in the revision history below.
10/01/2015	R3	LCD revised and published on 01-22-2015 to reflect the annual CPT/HCPCS code updates. CPT/HCPCS codes 80100, 80101, and 80102 have been deleted and therefore have been removed from the LCD.
10/01/2015	R2	LCD revised and published on 09/11/2014 to add ICD-10 diagnosis code Z71.51 to the covered diagnosis listing with an asterisk. Asterisks added to diagnosis codes Z79.891 and Z79.899. Asterisk explanation paragraph inserted for the above diagnosis codes.
10/01/2015	R1	LCD revised to accommodate provider commentary on the relationship between qualitative and quantitative methods of urine drug testing effective for dates of service on or after 10/01/2014 (LCD updated 06/06/2014)

All information on this web site is compiled directly from information obtained from the Center for Medicare and Medicaid Services (CMS) and from its Contractors.

CodeMap® has made every reasonable effort to ensure the accuracy of the information contained on this web site. However, the ultimate responsibility for correct coding and claims submission lies with the provider of services. CodeMap® makes no representation, warranty, or guarantee that this compilation of Medicare information is error-free or that the use of this information will result in Medicare coverage and subsequent payment of claims. Final coverage and payment of claims are subject to many factors exclusively controlled by CMS and its contractors.

No part of this web page or data displayed may be redistributed or used without the express written consent of Wheaton Partners, LLC.